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S Y N O P S I S 
SYNOPSIS 
The present work was undertaken to } ne! .oi t whether 
bradykinin played any part in anaphylaxis. The association 
of anaphylaxis with increased proteolytic activity pointed 
in this direction; further, the pharmacodynamic effects of 
bradykinin correspond to certain features of anaphylaxis. 
Only the antigen- antibody reaction of immediate -type 
anaphylaxis was studied. 
Certain special problems are inherent in such a study. 
Spontaneous formation and destruction of bradykinin in 
blood are known to occur very readily. Further, certain 
experimental manipulations such as the use of a thermo- 
cautery on skin would activate proteolytic enzymes with 
resultant formation and/or destruction of bradykinin. 
Particular care was therefore necessary to ensure that 
experimental manipulations by themselves did not influence 
the estimation of bradykinin levels. 
A method which neither forms nor destroys bradykinin 
was developed for estimation of blood bradykinin content. 
Using this, it was found that following challenge, there is 
a rapid but short -lived rise in blood bradykinin level in 
the sensitized guinea -pig, rat and rabbit. The increased 
activity in the post -shock samples was identified as 
bradykinin -like by parallel quantitative assay, relaxation 
of the rat duodenum, and destruction by chymotrypsin. In 
the rat it was shown that even when the actions of histamine 
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and 5- hydroxytryptamine are excluded by means of antagonists 
anaphylactic shock is followed by a fall in blood pressure, 
similar to that produced by bradykinin. The participation 
of bradykinin in anaphylaxis was confirmed by the observation 
that considerable depletion of plasma bradykininogen content 
occurs in prolonged anaphylactic shock. In order to 
demonstrate this, a technique was developed which gave a 
high yield of bradykininogen from small samples of blood. 
The amount of bradykininogen used up represents much more 
potential bradykinin than the peak bradykinin level would 
indicate. This points to a large turnover of bradykinin in 
such circumstances due to widely distributed kininase (i.e. 
bradykinin-destroying) activity. 
The release of bradykinin in vitro was also studied by 
challenging fresh blood of guinea -pig and rat, and blood - 
free isolated preparations of guinea -pi& lung and skin. A 
skin perfusion method was specially devised to avoid 
activation of proteolytic enzymes. When shed blood is 
challenged in vitro, no rise in blood bradykinin occurs. 
When isolated preparations of blood -free lung and skin are 
employed, bradykinin itself is not released, but the 
bradykinin -forming activity (BKF) of the perfusate is 
rapidly and markedly increased. This was estimated by 
measuring the amount of bradykinin formed under standard 
conditions by incubation of perfusate with the bradykinin- 
ogen present in heat -treated dog plasma pseudoglobulin. 
BKF release is initiated by antigen -antibody reaction itself 
and not the attendant histamine release, as shown by the 
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failure of administered histamine to induce BKF release. 
BKF is comparatively resistant to heat but it is 
destroyed by boiling. Its optimum pH is 6.5-7.0. It is 
not inhibited by the presence of disodium ethylenediamine 
tetra -acetic acid (EDTA) or hexadimethrine bromide. Thus 
BKF of lung tissue differs from the bradykinin- forming enzyme 
of human plasma. Soya bean trypsin inhibitor (SBTI) 
suppresses BKF activity. 
The kininase activity of normal lung perfusate is 
thermolabile and is not markedly inhibited with EDTA, 
hexadimethrine bromide or SBTI. The optimum pH value is 
7.0-7.4, with a sharp drop on the acid side. Thus at pH 
value 6.5-6.8 conditions are most favourable for bradykinin 
accumulation since formation is maximal and destruction 
submaximal. This may be important in pathological 
conditions such as reactive hyperaemia, trauma and burns 
where bradykinin may well play a role and where local 
release of acid metabolites would facilitate its occurrence. 
Bronohospasm and circulatory stasis might produce similar 
lowering of pH likely to lead to raised levels of 
bradykinin. 
These findings have been incorporated in a hypothetical 
scheme illustrating the dynamic state of bradykinin in 




Since the recognition of bradykinin as a separate 
entity and its recent synthesis, it has attracted wide 
attention. An increasingly large volume of work has been 
and is being done to elucidate its occurrence, metabolism 
and role in health and disease. The present investigations 
were aimed at exploration of its role, if any, in immediate- 
type anaphylaxis. In this chapter an attempt has been 
made to give a pertinent résumé of the pharmacology of 
bradykinin and a summary of present knowledge concerning 
biochemical events of anaphylaxis. 
BRADYIQNIN 
The appearance in blood of a substance which produces 
vasodilatation and slow contraction in plain muscle has 
been known for some time. Werle, Götze and Keppler (1937) 
reported that kallikrein, acting on blood in vitro, formed 
a smooth muscle stimulating substance. It had been shown 
earlier that a vasodilator substance 'Frúhgift' was formed 
spontaneously from cat platelet suspension (Freund, 1920, 
1921). Intravenous saliva also has been known to lower 
blood pressure (Feldberg and Guimarais, 1935). It was 
thought that protein split products produce these effects 
in the above oases. The distinct identity of bradykinin 
was established when Roche e Silva, Beraldo and Rosenfeld 
(1949) identified a substance formed by incubating snake 
venom or trypsin with ox serum, as distinct from histamine 
and acetylcholine. This produced a slow contraction of 
isolated guinea -pig ileum preparation, and was accordingly 
5 
named. bradykinin. 
Physical and Chemical properties: 
Bradykinin is very stable to heat, and resists 
prolonged boiling with distilled water or dilute acid. It 
resists 0.1 N NaOH for two hours at room temperature, but 
on boiling it is destroyed in a few minutes. It is freely 
dialysable, is soluble in ethanol, but not in anhydrous 
acetone or ether. It gives a strong ninhydrin reaction. 
Using the procedure of stepwise degradation and separation 
of the various products by two -dimensional chromatography, 
bradykinin has been found to be a nonapeptide with a 
molecular weight of 1131 and the following amino -acid 
structure: Arg. Pro. Pro. Gly. Phe. Ser. Pro. Phe. Arg. 
(Elliott, Lewis and Horton, 1960). Synthesis by 
Boissonas and his co- workers has confirmed this structure 
( Boissonas, Guttman and Jaquenoud, 1960a, 1960b; 
Boisson s, Guttman, Jaquenoud, Konzett and Stürmer, 1960). 
PHARMACODYNAMIC PROPERTIES OF BRADYKININ: 
The important features are slow contraction of smooth 
muscle, vasodilatation, increased capillary permeability, 
production of pain and leucocyte migration. 
Bradykinin produces a contraction in many isolated 
smooth muscle preparations - rat uterus, guinea -pig ileum, 
rat stomach, rabbit duodenum, rat colon and guinea -pig 
uterus. Rat uterus is the most sensitive preparation 
and contracts at 10 
10 
g/ml. (approximately 10 
10 
M). 
The slow onset of contraction is characteristic of the 
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substance. In preparations like rabbit intestine with a 
spontaneous motility of its own, there is a transient phase 
of relaxation, which is followed by contraction. Rat 
duodenum, however, has a purely relaxant response, without 
any contractile effect. This distinguishes bradykinin 
from other plain muscle stimulating substances, and helps 
in its identification. It has no milk ejection effect 
(Berde and Cerle tti, 1961). 
Bradykinin lowers blood pressure in various species 
- rabbit (0.05 jag/kg), dog, rat and guinea -pig (0.2 pg/kg), 
cat (0.5 A /kg) and rooster (40 -80 jag/kg) (Konzett and 
Stürmer, 1960). This drop in blood pressure is due to 
capillary dilatation. The hypotensive response in cat is 
accompanied by an increase in kidney volume, as shown by 
renal plethysmography. 
The vasodilator activity of bradykinin has been 
observed in animals and man (Alfonso, Rowe, Castillo, Lowe 
and Crumpton, 1962). In man, the vasodilator effect is 
greater after interarterial administration than when given 
i.v.; this has been attributed to varying rates of 
destruction (Kidd and Lewis, 1960; Fox, Goldsmith, Kidd 
and Lewis, 1961). On a molar basis, bradykinin is a more 
potent vasodilator than acetylcholine, histamine or 
isoprenaline. 
Rocha e Silva, Corrado and Ramos (1960) found that 
hexamethonium did not influence significantly the hypo- 
tension produced by bradykinin, though chlorpromazine, 
dibenzyline, apresoline and reserpine prolonged the duration 
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of this bwpotension, cocaine reduced the extent and duration 
of hypotension, but when followed by dibenzyline, this 
effect was not manifested. All these effects would seem to 
be due to modification of the normal reflex vasoconstriction 
or circulatory noradrenaline. 
Bradykinin enhances capillary permeability. This can 
be seen in the guinea -pig blueing test (Bhoola, Calle and 
Schachter, 1960) and in the rat paw oedema test (Sturmer and 
Cerletti, 1961). 
In keeping with its plain muscle stimulant activity, 
the general effect of bradykinin on the respiratory system 
is that of bronohoconstriction, as has been shown in vivo in 
guinea -pig lung and in spinal oat (Collier, Eolgate, 
Schachter and Shorley, 1960; Konsett and Stürmer, 1960). 
Isolated bronchioles are surprisingly unreactive. Collier 
et al (1960) have mentioned a bronchodilator component of 
bradykinin activity in some species which can be unmasked 
when the bronchoconstrictor component is antagonized by 
antipyretic antagonists. In dog, the respiratory rate and 
volume rises (Konzett and Stürmer, 1960); in the bronchi, 
either some dilatation occurs, or there is no effect 
4 Stresem. rn. 
(Hasler, 1961). Herxheimer6(1961) have reported that 
bradykinin aerosol produces moderate bronch000nstriction in 
asthmatic man, while there is no effect in normal man. Pure 
bradykinin, applied to blister base, produces pain (Elliott, 
Horton and Lewis, 1960). Peri capillary non- myelinated 
fibres and branching varicose terminals around blood 
vessels may be similar to free branching 'pain' receptors 
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in cutaneous epithelium (Weddell and Pallie, 1954; Lim, 
1960). Braun, Guzman, Horton, Lim and Potter (1960) found 
that intra- arterial injection of bradykinin to lightly 
anaesthetised dogs produces vocalisation, hyperpnoea and 
vasomotor changes which they have attrtibuted to the pain - 
producing effect. Guzman, Braun and Lim (1962) suggest 
that the response is a reflex phenomenon, arising from the 
pain -endings. 
The central effects of bradykinin do not seem to have 
been investigated in much detail. Roche e Silva (1960) 
refers to some unpublished experiments of Corrado and Ramos 
where bradykinin given via intraventricular cannula to 
unanaesthetised cat caused hypotension, sometimes tranquil- 
lisation and relaxation of the nictitating membrane, though 
some animals became restless and went into convulsions. 
Capek (1961) reported that under similar circumstances motor 
disturbances - musoular twitches leading to tonic 
convulsions - occurred. Hyperventilation, salivation, 
micturition and mydriasis occurred. Behaviour changes also 
appeared - the slightest touch caused continuous phonation 
and the animals lay down in bizarre positions. Similar 
events occurred in mice also on intracerebral injection of 
bradykinin. Bradykinin increased the convulsive activity 
of leptazol and strychnine. 
Bradykinin via -á vis Kallidin: 
Kallidin, produced by incubating kallikrein with 
bovine and dog serum was found indistinguishable from 
bradykinin pharmacologically (van Arman and Miller, 1961). 
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Pierce and Webster (1961) found that kallidin consists of 
kallidin I, which has the same chemical structure as 
bradykinin, and kallidin II, which is a decapeptide with a 
'closely similar amino -acid sequence - H. Lys. Arg. Pro. Pro. 
Gly. Phe. Ser. Pro. Phe. Arg. Kallidin II has recently 
been synthesized (Nicolaides and De Wald, 1962). Kallidin 
II has the same pharmacodynamie properties as bradykinin, 
though it is only half as active (Pierce and Webster, 1961). 
ANTAGONIST DRUGS: 
Acetylsalicylic acid, phenylbutazone and amidopyrine 
have been found to antagonize bradykinin bronchoconstriation 
in vivo in guinea -pig, in doses in which bronchoeonstriction 
due to histamine and 5- iydroxytryptamine were not affected 
(Coll.ier, Holgate, Schachter and Shorley, 1960; Collier 
and Shorley, 1960). Increasing doses of bradykinin over- 
came this antagonism which could be restored with increasing 
doses of the antagonist. When other test objects were em- 
ployed, no antagonism could be shown with these compounds 
except as part of a general depressant response. To 
explain this, the above workers have suggested that brady- 
kinin may act on more than one kind of receptor, whereas 
antagonists have a narrower range of action. There does 
not seem to be enough evidence for any satisfactory 
conclusion, as antagonism could be shown only on living 
in vivo plain muscle which is more sensitive in vivo than 
in vitro to bradykinin whereas most other plain muscle 
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preparations (intestine, uterus) are more sensitive in 
vitro. Further information is clearly desirable in this 
field. 
Phenylbutazone has been reported to suppress the 
lowering of blood pressure in rabbit by bradykinin, but the 
high dosage employed (100 mg/kg) detracts from the 
significance of these findings ( Lecomte, 1959; Lecomte and 
Troquet, 1960). 
Braun, Guzman, Norton, Lim and Potter (1960) have 
reported that the algesio response of lightly anaesthetised 
dogs to bradykinin (vocalisation, byperpnoea and cardio- 
vascular changes) are partially or completely blocked by 
acetylsalicylic acid or N- acetyl -para- aminophenol. 
SOURCE OF BRADYRININ: 
Plasma contains the precursor of bradykinin in the 
euglobulin fraction, but it has never been isolated and 
characterised. Bradykinin precursor is usually called 
bradykininogen, and more than one protein may be involved. 
In the absence of adequate fractionation methods, bradykinin 
-forming enzymes have so far been tested only on relatively 
crude samples of bradykininogen. Quantitative studies in 
bradykinin formation are difficult in these samples because 
several reactions proceed simultaneously: (a) formation of 
bradykinin, (b) destruction of bradykinin due to kininase 
activity, and (c) inhibition of bradykinin- forming enzyme 
by an inhibitor, also present in the substrate. 
Attempts have been made to dissociate bradykininogen 
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from these interfering substances. One approach has been 
to heat the material, with or without acid -denaturation. 
The enzyme inhibitor present in plasma is said to be 
destroyed by heating at 56° for 3 hours (Werle, 1934; 
Werle, Götze and Happier, 1937). Lewis (1960) states that 
this method reduces but does not eliminate the inactivator. 
Van Arman (1955) denatured plasma by boiling with acetic 
acid to eliminate interfering substances. This preparatio 
however, is unsuitable for comparatively slow- acting 
enzymes (Lewis, 1960). Horton (1959) found that if dog 
plasma paeudoglobulin is incubated at 37 °0 and pH 2 for 15 
minutes and then neutralised, kininase and enzyme 
inhibitor are destroyed. Acidification might be expected 
to activate kallikreinogen (Frey, Kraut and Werle, 1950) 
and thus form kinin during such incubation, but Horton 
showed that the incubation mixture contains the same amount 
of kinin before and after incubation. Of the substrates 
available, this preparation is the best at present used 
for investigation of bradykinin-forming enzymes. 
Another approach has been to fractionate plasma to 
dissociate interfering enzymes from bradykininogen (Rocha 
e Silva, Beraldo and Rosenfeld, 1949). They precipitated 
plasma with 50% ammonium sulphate saturation at first but 
later it was found that better yields were obtained with 
fractional precipitation between 33% and 46% saturation. 
However, interfering enzymes were present in this 
preparation also. In any case, the protein content of 
pseudoglobulin preparation precipitated between 33% and 4.6% 
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ammonium sulphate saturation is quite mixed, the yield from 
100 ml serum containing 0.15 g albumin, 0.12 g d globulin, 
0.55 g at2 globulin, and 0.67 g of p- and gamma -globulins 
combined (Lewis, 1960). The presence of the precursor of 
a kinin- forming enzyme in serum, which may be kallikrein- 
ogen or plasminogen or both, further complicates matters. 
Plasminogen activators, when added to pseudoglobulin enhance 
kinin formation. 
The globulin fraction containing bradykininogen varies 
from species to species. Verle (1955) had investigated ox 
plasma by paper eleotrophoresis and aqueous elution. He 
found that bradykininogen occurred in o42- globulin, but not 
a1- 
globulin or albumin. Kininase activity is associated 
with this fraction, which reduces its suitability for use 
as a substrate. Van Arman's experiments (1955) suggest 
that the ß -globulin fraction is more important than cc- 
globulin for bradykinin formation in human serum with 
Bothrops jararaoa venom. In terms of Cohn's fractions, 
van Arman (1955) found that fraction IV was the only one 
which formed bradykinin; of this fraction, IV-1f yielded 
more bradykinin than IV-1. The former contains more p - 
than a-globulin, while the reverse occurs in the latter. 
Further support was available from eleotrophoresis experi- 
ments where he found that of the three peaks, o-globulin, 
0 -globulin and albumin, only p -globulin was reduced by 
bradykinin formation. Preparation of a purified substrate 
free from enzymes or their precursors is essential before 
the finer details of bradykinin formation can be elucidated. 
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It may be possible to isolate bradykininogen with the more 
recent methods of protein fractionation. 
FORMATION OF BRADYKININ: 
The physiological and pathological modes of bradykinin 
formation are not fully known. Trypsin and certain snake 
venoms were originally employed in the preparation of 
bradykinin. Apart from these, bradykinin is also formed 
by kallikrein, plasmin, glass -activation, and dilution of 
plasma. 
Ballikrein: 
The presence of a hypotensive substance in urine was 
first reported by Abelous and Bardier (1909) and Pribram 
and Herrnheiser (1920). Frey and Kraut (1925) called it 
'Kallikrein' after the Greek woH%JLAltljeaj meaning 
pancreas, because they thought it was a pancreatic hormone 
with cardiovascular activity, but later it was recognised 
to be an enzyme, which forms kallidin from serum globulin. 
At present kallikrein is not a very specific term and may 
even cover more than one enzyme. 
Iallikrein was formerly assayed by its vasodepressor 
effect on dog blood pressure. It was found later that the 
amount of kallidin formed from heated acid-treated dog 
plasma pseudoglobulin on incubation under standard 
conditions is proportional to the amount of kallikrein 
incubated (Horton, 1959). This method is now in general 
use. 
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Formerly it was thought that kallikrein was found 
solely in the pancreas. It is now known that pancreas is 
neither the sole nor the major source of kallikrein (Beraldo, 
1952; Beraldo, Feldberg and Hilton, 1956). Kallikrein is 
found in considerable amounts in pancreas & salivary gland; 
a plasma kinin forming enzyme is also found in skin (Fox 
and Hilton, 1958), cerebrospinal fluid (Chapman and Wolff, 
1958) and lachrymal secretion (Lewis, 1959). 
Kallikreein produces its pharmacological effects through 
formation of kallidin which has the same properties as 
bradykinin. It has been claimed, though not confirmed, that 
kallikrein by itself, and not via kallidin formation 
contracts dog intestine. 
Blood contains kallikreinogen, an inactive precursor 
of kallikrein. Frey, Kraut and Werle (1950) suggested 
that kallikrein from pancreas or salivary glands travelled 
to the blood stream, either by direct internal secretion, 
or indirectly by resorption from the intestinal tract. As 
for the salivary gland, it has no mechanism for internal 
secretion, nor would kallikrein survive gastric acidity. 
Werle (1960) found that in a ligated submandibular duct, 
kallikrein disappears long before histological changes 
occur. Transfer of salivary gland kallikrein to blood 
thus seems unlikely. As regards pancreas, there is some 
evidence against resorption of kallikrein through the 
intestinal wall (van Winkle, 1941). Endocrine 
adsorption of pancreatic kallikrein is also iiniike]y 
because it has been shown that kallikrein level does not 
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change with experimentally induced degeneration of ß - or 
other cells. 
Different forms of kallikrein: 
Kallikrein from different sources have been attributed 
slightly different properties. "Ornitho- kallikrein" (of 
avian origin) forms kallidin from avian but not mammalian 
sera, and mammalian kallikrein acts on mammalian but not 
avian sera. 
lCallikreinogen: 
ICallikrein is not present in an active form in blood. 
It is present in combination with an inactivator. The 
term 'kallikreinogen' has been applied to this inactive 
condition. Apart from pancreas, Werle and Vogel (1960e) 
found kallikreinogen in the wall of the small and large 
intestine of man, rat, dog, cat and cattle. Pancreas is 
not a major source of kallikreinogen, since pancreatectomy 
in dog or rat does not reduce kallikreinogen content of 
serum or intestine (Werle and Vogel, 1960). The source 
could be liver, since experimental liver damage with 
carbon tetrachloride in rat, and liver disease in man, is 
associated with a low blood kallikreinogen content. The 
kallikreinogen content of liver is higher than that of 
blood, so this subject needs further study. 
It is not yet known how physiological activation of 
kallikreinogen takes place. Blood contains very little 
active kallikrein, but normal urine contains a fair amount 
of it. Activation of kallikreinogen may be one of the 
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physiological events in the kidney. Investigating this 
possibility, Werle and Vogel (1958, 1960b) found that when 
experimental renal damage is induced in rats with uranyl 
acetate or t t45a,Ly.i s kallikrein disappears from urine, but 
kallikreinogen starts to appear. If the renal damage is 
reversible, these changes disappear later. Kallikreinogen 
has also been found in human nephrotic urine ( Werle and 
Vogel, 1958). These authors (1960) have suggested that 
kallikreinogen is activated by tubules. This appears to be 
possible, but there are other possibilities - e.g. 
alteration of pH, tonicity, etc. It would be interesting 
to know if the glomeruli will pass kallikrein, but not 
kallikreinogen. 
Blood kallikreinogen has been activated in vitro by 
acidification, acetone treatment, and treatment with papain 
(Frey, Kraut and Werle, 1950). Acidification to pH 2 
releases considerable quantities of kallikrein in blood. 
As acid metabolites may lower pH locally, this may be of 
importance in physiological activation, though pH 2 is 
unlikely to occur in the course of physiological events. 
Activation of kallikreinogen can also be produced on 
treatment with acetone or papain. 
Kallikrein inactivation: 
The existence of a kallikrein inhibitor in blood was 
realised somewhat fortuitously when Frey and his colleagues 
found that samples of urine collected after a long period 
of experimentally induced reflex anuria, and strongly 
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positive when tested for the presence of blood, had little 
effect when tested for kallikrein on the cardiovascular 
system (Frey, Kraut and Werle, 1950). These workers found 
an inactivator substance in blood and several other tissues. 
It should be remembered that antiproteolytic activity in 
blood has been known for many years, and probably is of 
little specificity. 
Kallikrein inactivator effect has been found in other 
sources also: bovine parotid gland (Kraut and Korbel- 
Enkhardt, 1957); blood of the vineyard snail Helix pomatia 
( Werle, Appel and Happ, 1958); and potatoes ( Werle and 
Maier, 1955; Werle, Maier and Löffler, 1951). 
Northover and Subramanian (1961) studied the effect of 
analgesic- antipyretic drugs in vitro on kallidin formation 
by guinea-pig serum kallikrein or human salivary kallikrein. 
They found that some of these agents (phenylbutazone, 2:6- 
dihydroxybenzoic acid, NaOC.- 14.sec- butyl- phenoxyprop onate, 
aspirin and salicylate) inhibited kallidin formation in 
concentrations which did not affect the smooth muscle 
stimulant activity of kallidin or bradykinin. These 
concentrations were much lower than those necessary for 
general anti- enzyme activity (Lutwak -Mann, 1942). 
Plasmin: 
Plasmin is a proteolytic enzyme normally present in 
blood in an inactive form, plasminogen. When this is 
activated, proteolytic activity of blood increases. In 
view of the raised proteolytic activity, plasmin was 
investigated for bradykinin- forming activity by different 
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workers. Beraldo (1950) showed that plasmin, on 
incubation with plasma, forms a bradykinin -like substance. 
Lewis and Work (1957) reported the slow development of 
bradykinin -like activity on incubation of human plasmin 
with dog plasma pseudoglobulin, whereas plasminogen, the 
active precursor had neither proteolytic nor bradykinirr 
forming properties, though these properties appeared on 
addition of the specific activator streptokinase. Weight 
for weight crystalline trypsin has a greater bradykinin- 
forming activity than plasmin. When amounts of trypsin 
(presumably caseololy}ic or fibi4nolytìc 
and plasmin which have equal proteolytic^activity are 
compared for bradykinin- forming activity, plasmin forms 
more bradykinin than trypsin (Lewis, 1960). Intravenous 
plasmin reduces blood pressure in dog, probably due to 
bradykinin formation. If administered repeatedly, its 
response is gradually reduced probably due to gradual 
substrate (i.e. bradykininogen) depletion. After such 
depletion by plasmin, the hypotensive effect of kallikrein 
is reduced and vice versa. Eisen (1961) found that when 
"pre- active" (i.e. plasma not previously subjected to 
activation processes) human plasma is incubated with plasmin 
kinin formation commenced in about thirty seconds, reaching 
the peak in about five minutes. The activity fell to a low 
level in 20 to 30 minutes. These workers considered plasmin 
as a quick- acting enzyme, since it acted as rapidly as 
glass- activation. Formation of bradykinin by plasmin is 
inhibited by antiplasmin (Lewis, 1958). Soya bean trypsin 
inhibitor (Lewis, 1958; Schachter, 1960) inhibits kinin 
formation by plasmin as also kallikrein; the latter is not 
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inhibited by ovomucoid trypsin inhibitor ( Sohachter, 1960). 
The possibility of kallikrein being involved in plasmin 
activity has been explored (Schachter, 1956; Lewis, 1958; 
Webster and Pierce, 1960). These enzymes can be 
distinguished by their response to heat and acidity. These 
are very similar with regard to their relationship to 
inhibitors, so that they can be distinguished only by the 
ratio of trypsin inhibitors required to inhibit these 
enzymes; the approximate ratio of SBTI, OTI and PTI are 
1:10:100,000 for plasma kallikrein as compared to 1.0:0.36: 
1.77 for plasmin (Green, 1953). Furthermore, o,o -bis- 
(2- chloro- ethyl)- o- (2,2- dichlorovinyl) phosphate inhibits 
plasma kallikrein, but not plasmin. 
Werle (1955) found that acetone treatment of plasma 
activates proteolytic enzymes which act on kallikreinogen, 
forming kallikrein. Investigating this, Webster and 
Pierce (1960) suggested that plasmin was not the protease 
concerned, since ovomucoid did not inhibit acetone activat- 
ion of plasma kallikrein and acetone did not activate 
plasminogen. They also observed that SBTI did not 
inhibit splitting of kallidinogen in the presence of 
streptokinase, and suggest that it is possible that 
streptokinase activates not only plasmin but also other 
kallidinogen- splitting proteases, though any such have not 
been identified so far. 
Activation of plasminogen: 
A number of substances activate plasminogen to plasmin. 
These may be present in bacterial cells (staphylokinase and 
* Trypsin inhibitors from soya bean oVOmIt.coid arlo( 
pancreas respe wely, 
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streptokinase), in normal urine ( urokinase), in blood and 
other tissues (Müllertz, 1956). The activators found in 
skin, lung and brain are insoluble in water and can be 
brought out in solution only with thiocyanate ( Goldhaber, 
Cornsman and Ormsbee, 1947; Tagnon and Feterman, 191+9; 
Lewis and Ferguson, 1950; Astrup and Sterndorff, 
1956 ) . 
When tissue plasmin activator from skin or urokinase is 
incubated with bradykininogen- containing pseudoglobulin sol- 
ution, plasma kinin is formed (Lewis, 1959; Horton and 
Lewis, 1960). However, streptokinase incubated with pseudo - 
globulin does not form plasma kinin unless plasminogen is 
present (Lewis, 1959; Horton and Lewis, 1960). This is 
probably due to the fact that a "pro-activator" is necessary 
for activating the streptokinase; the "pro- activator" is 
present in plasminogen, and hence addition of plasminogen 
sets the activation mechanism in motion (Müllertz and Lassen, 
1953; Lewis, 1959; Horton and Lewis, 1960). The proteo- 
lytic activity of blood is balanced delicately between 
plasmin, plasmin inactivator (antiplasmin) and an "anti - 
inaetivator" (Müllertz, 1956). The role of plasmin in the 
physiological formation of plasma kinin is not yet clear. It 
has been invoked in glass -activation and dilution- activation, 
as discussed later. In any event it is activated in vivo in 
a number of conditions, and could lead to raised levels of 
bradykinin and thus contribute to the overall picture. 
"Quick- acting" and "Slow -acting" bradykinin- forming enzymes: 
Lewis mentions (1960) that while the rate of enzymic 
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conversion depends on substrate concentration - plasma 
bradykininogen in this case - kallikrein never takes more 
than 10 to 15 minutes for maximal kinin formation ("quick - 
acting eng me ") and urokinase, probably acting through 
plasmin, never less than 20 to 30 minutes ("slow-acting 
enzyme "). Eisen (1961) does not agree with this division; 
under his experimental conditions, plasmin could produce 
maximal bradykinin formation within very few minutes. 
Menue this division between "quick -acting" and "slow - 
acting" enzymes will need further exploration and confirm- 
ation. The discrepancies are probably due to the very 
impure enzymes and substrates used. 
Glass- activation: 
Plasma, blood and inflammatory exudates have been 
shown to form a pain - producing substance on contact with 
glass (Armstrong, Dry, Keele and Markham, 1953; Armstrong, 
Mobbiger, Jepson and Keele, 1953; Armstrong, Jepson, 
Keele and Stewart, 1954, 1955 and 1957). This substance 
can be assayed on rat uterus. The activity reaches a 
peak in a few minutes, but declines by 90 in an hour. 
After glass -activation and decay, re- activation by a 
second exposure to glass is not possible, though these 
samples can activate "pre -active" plasma, thus showing 
that enzyme or activator was still present after all the 
substrate was used up. The active substance closely 
resembles bradykinin. Margolis (1958) postulated that 
exposure to glass activated an inactive plasma factor 
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( "component A ") to an active factor ( "contact factor ") for 
which Hageman Factor was essential. Contact factor 
combines with another factor ( "component B ") in blood and 
liberates plasma kinin. Lewis (1958, 1960) suggests 
that this could be the plasminogen -plasmin system. 
However, epsilon- aminocaproic acid (EAC) does not inhibit 
glass activation, though it inhibits formation of kinins 
by plasmin. EAC has even some kinin -forming capacity of 
its own. The speed of glass- activation is also in 
contrast with the relatively slow action of plasmin. 
Activation by dilution: 
Schachter (1955) has shown that when serum or plasma 
of guinea -pig, rabbit, rat, cat, dog and man is diluted 
optimally with physiological solution, bradykinin -like 
activity develops and later decays. Plasma previously 
depleted of bradykininogen by trypsin could not be 
activated by dilution. Plasminogen is activated by 
dilution (Macfarlane and Pilling, 1946), and diluted 
guinea -pig serum has been shown to develop a substance 
which increases capillary permeability (Mackay, Miles, 
Schachter and Wilhelm, 1953; Miles and Wilhelm, 1955) . 
Schachter found that dilution- activated plasma and 
kallikrein are similarly affected by soya bean trypsin 
inhibitor, and heating at 56 °C for 3 hours. He has 
therefore suggested (1956) that dilution activates 
kallikreinogen to kallikrein which then proceeds to form 
plasma kinin. 
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Recently, Eisen (1961) has reported that both 
dilution- activation and glass- activation of human plasma 
are due to the same enzyme. Armstrong et al. (British 
Pharmacological Society Winter Meeting, 1962) reported that 
a purified preparation of this enzyme, homogenous on 
electrophoresis was antagonised by polybrene, an antagonist 
of heparin. This distinguishes it from plasmin. 
DESTRUCTION OF BRADYKININ BY KININASE: 
Kallidin is inactivated on incubation with serum or 
plasma ( Werle, 1955). Kininase activity has been found in 
the serum of guinea -pig, cat, dog, ox and man, guinea -pig 
serum being the most potent (Schachter, 1960). Destructive 
activity was found to be similar in serum and lymph 
collected from the thoracic duct. In blood,kininase 
activity has been found in formed elements also (Erdós, 
Renfrew, Sloane and Wohler, 1962; Schwab, 1962). Werle 
(1955) found kininase activity in his ee globulin prepared 
by precipitation with ammonium sulphate. Edery and Lewis 
(1962) found that kininase activity is very much depressed 
at pH 6.5. Werle (1960) has reported increased serum 
kininase activity during the terminal weeks of human 
pregnancy. 
Kininase activity has been reported in various organs 
including kidney and liver. Hamberg and Rocha e Silva (1954) 
distinguished a bradykininase from a histaminase present 
in hog kidney. The kininase activity was not associated 
with oxygen consumption, and the optimum pH was > 7.4; 
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this sets it apart from ensymes like beef spleen cathepsin I 
which is reported to have pH 5.4 as optimum value (Bergman, 
1941). Kininase activity has been found in liver tissue, 
but the organs in these experiments were not blood -free and 
it is not known how much was due to blood (Aerie, 1955). 
Chymotrypsin has a potent kininase activity. Early reports 
attributed kininase activity to trypsin also, but this is 
now known to be due to chymotrypsin contamination. 
Cysteine has been reported to inhibit kininase 
(Picarelli, Henriques and Oliveira, 1962). As cysteine 
potentiates bradykinin- induced contraction in plain muscle, 
any evaluation of its anti -kininase activity needs special 
care. 
ROLE OF BRADYKININ IN NORMAL AND PATHOLOGICAL STATES: 
Despite widespread interest and much work, there is as 
et no comprehensive picture of the role of bradykinin in 
normal and pathological states. There is good evidence that 
it acts in functional vasodilatation of salivary secretion 
and in sweating, but only suggestive evidence of involvement 
in various other phenomena. 
In functional vasodilatation of salivary secretion: 
Hilton and Lewis (1956 et seq.) investigated the 
possibility of bradykinin acting as a mediator for 
functional vasodilatation accompanying activity in salivary 
gland and muscle. Employing the technique of intermittent 
Tyrode perfusion of cat submandibular gland, they found 
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that when the gland was stimulated by cholinergic or 
adrenergio drugs or parasympathetic or sympathetic 
stimulation, the perfusate showed hypotensive activity. 
Smooth muscle stimulant activity was not present as such 
in the perfusate, but developed when perfusate was 
incubated with plasma. The similarity in the time -course 
of development of hypotensive response and development of 
smooth muscle stimulant activity suggested the same active 
principle was responsible for both the properties. When 
saliva + pseudoglobulin and perfusate + pseudoglobulin 
4x.fiures were compared with bradykinin, parallel 
quantitative tests showed good correspondence and no 
distinction could be found with simple physiochemical 
testa. The forming enzyme was evidently present in 
saliva also, and this gave new significance to older 
findings ( Senker, 19343 Feldberg and Guimarais, 1935) that 
saliva had hypotensive, but not smooth muscle contractile 
properties. The small amount of bradykinin- forming 
activity in perfusate from non -stimulated gland increased 
2.5 to 8.5 times after stimulation. Employing the 
technique of circulatory arrest, Milton and Lewis (1956) 
concluded that the enzyme- substrate reaction takes place 
not in the circulating blood but in the interstitial fluid. 
Bradykinin precursor has not yet been shown specifically in 
interstitial fluid, but mammalian lymph, a closely allied 
material has been shown to contain all the fractions in 
mammalian plasma (Yorfay and Gourtice, 1956). From their 
experiments, Milton and Lewis (1956) concluded that when 
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salivary gland secretes, no matter how it is stimulated to 
do so, a plasma -kinin forming enzyme escapes into the 
interstitial spaces of the gland and forms plasma kinin 
which acts as the mediator for the vasodilatation which 
accompanies glandular activity. 
Vasodilatation in the tongue, produced by stimulation 
of hypogloasal and ohordo - lingual nerves was also investig- 
ated (Hilton and Lewis, 1958). Chordo - lingual stimulation 
was found to increase the enaymic activity twofold or more. 
The authors considered and excluded antidromic stimulation 
as the causal factor. They concluded that a bradykinin- 
forming enzyme, released during stimulation of the tongue, 
formed bradykinin. Their findings suggested that 
activation of the glandular, and not muscular, element of 
the tongue is involved in the process. 
Bradykinin and cutaneous blood flow: 
Bradykinin has been investigated as a possible 
mediator of functional vasodilatation of sweating (Fox and 
Hilton, 1958). Bradykinin- forming activity was found 
like saliva in human eccrine sweat, but not in the 
perfusate obtained from the subcutaneous space in man. 
Subcutaneous perfusate, however, contained bradykinin -like 
activity. These workers excluded the possibility of 
bradykinin formation by dilution of plasma with saline by 
showing that the tyrosine content of the perfusate did not 
rise. Fox and Hilton (1958) concluded that in human 
eocrine sweat glands, bradykinin formation produces a 
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pZriglandular vasodilatation, and thus plays an important 
role in sweat secretion; and that forearm vasodilatation 
during body heating is mainly induced by bradykinin formed 
by sweat gland activity. 
Lewis (1960) has questioned these conclusions. 
Increased amounts of blood flowing through the capillary 
bed, however mediated, with diffusion of saline into 
capillaries, will lead to formation of bradykinin due to 
dilution- activation. In such a case, the subcutaneous 
perfusate should contain kinin, but no kinin- forming 
enzyme. However, if activated sweat glands released 
enzyme in the periglandular space, the perfusate should 
contain some kinin-forming enzyme. As the matter stands 
at present, Fox and Hilton's (1958) experiments have 
established a role for bradykinin in functional 
vasodilatation in sweating, but it is not known whether other 
mechanisms are involved. 
Bradykinin- forming activity occurs in other glands 
e.g. lachrymal and pancreatic. Lewis (1959, 1960) pointed 
out the wide concurrence of gland activity with 
bradykinin formation, and suggested that in general function- 
al vasodilatation accompanying glandular activity may be 
mediated by local formation and release of plasma kinins. 
Bhoola, May May Ti, Morley and Schachter (1961) do not 
agree with this suggestion. They have pointed out that 
guinea-pig saliva does not form kinin from its own plasma, 
though kinin is formed from heterologous plasma; liver, 
gastric mucosa and other glands of guinea -pig have no 
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kinin- forming activity; and furthermore, accessory sex 
glands from rat, rabbit, cat and man have no kinin-forming 
activity. 
Dradykinin in burns: 
As bradykinin produces both vasodilatation and increas- 
ed capillary permeability it may be one of the substances 
released in thermal damage. Rocha e Silva and Rosenthal 
(1961) found that histamine, bradykinin and adenosine 
compounds appeared in the fluid in an air pouch on the 
dorsum of rats, heated at 96 °C for 15 seconds. The authors 
have suggested that the amount of bradykinin present follows 
that of histamine, but more evidence is necessary before 
this can be accepted; in any case the heating is very 
severe..:: .. , s:: 4 Fw of ad ,B:; ^r. 1Dou as. The 
effect of various temperatures has also been studied in rat 
forelimbs perfused by a coaxial cannula (Roches e Silva and 
Antonio, 1961). At 37 °C the perfusate was inactive; at 
10°- 4.5°C bradykinin -like activity appeared, but histamine 
appeared only at 57 °C or above. The authors suggest that 
protease activation due to thermal damage acts on bradykin- 
inogen and releases bradykinin. Thermal damage has long 
been known to produce increased proteolytic activity. On 
the basis of evidence available so far, involvement of 
bradykinin in burns appears likely, but further work remains 
to be done. 
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Bradykinin in central nervous system activity: 
Normal and pathological human cerebrospinal fluid has 
been investigated for smooth muscle stimulant activity, as 
for 
well as bradykinin- forming activity. Chapman and his 
co- workers (Chapman and Wolff, 1958, 1959; Chapman, Goodell 
and Wolff, 1959a, 1959b; Chapman, Ramos, Corrado, Forbes 
and Symes, 1960) reported that specimens from persons with 
no active lesion of the central nervous system had at most 
traces of oxytocic or bradykinin-forming activity. Specimens 
from patients with active inflammatory or degenerative 
conditions were usually aotive. They later found (1960) 
that when the sciatic nerve or brain of cat was electrically 
stimulated briefly, effluent from perfusate cerebral 
ventricle showed a transient increase in bradykinin- forming 
activity. The above -mentioned findings in human subjects 
could not be confirmed by Coppen and Lewis (1961) who found 
that enzymic activity, present in about one -quarter of 
samples studied were distributed randomly among patients 
with and without central nervous system disorders. Since 
these findings are in conflict, it should be noted that 
Chapman and his co- workers employed an unsatisfactory 
pharmacological test. They tested a fixed amount of 
cerebrospinal fluid, alone or after incubation with pseudo - 
globulin, and noted the presence or absence of contraction 
in rat uterus. All results were "negative ", or "type I" or 
"type II ", and all these contractions were small, as judged 
by the tracing illustrated. No attempt was made to express 
the amount of activity, in terms of a standard substance. 
In view of the very steep dose -response slope of bradykinin 
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on rat uterus, this kind of evaluation will greatly 
exaggerate any difference between "negative" or "type I or 
II" results, particularly if the negative results are due to 
quantities of bradykinin which are only slightly 
subthreshold. 
Bradykinin and colostrum: 
Urinary kallikrein, or calf saliva on incubation with 
bovine colostrum develop s smooth muscle stimulant activity. 
The active principle, called colostrokinin is similar to 
plasma kinin (Guth, 1959, 1960). Plasma kinin is more 
akin to urine- colostrokinin than saliva- colostrokinin, as 
judged by parallel quantitative assay. Suckling by the 
newborn results in incubation of colostrum with saliva, 
presumably leading to formation of saliva- colostrokinin. 
It is postulated that this may facilitate the passage of 
protein from the neonatal gut to the blood (Guth, 1959), 
thus permitting the absorption of antibody gamma -globulin 
in the newborn. As colostrum is replaced by milk, the 
kinin- forming activity disappears. 
Bradykinin in pregnancy and parturition: 
Little information is available on this aspect. The 
amount of kinin formed by various activation procedures 
declines during labour, and is at its lowest at the end of 
the second stage of labour indicating an increased utilisat- 
ion of bradykinin (Armstrong, Keele and Stewart, 1955). 
Human amniotic fluid has been shown to have bradykinin -like 
activity (Van Den Dreissehe, 1960). Furthermore, in pregnant 
women kininase activity in serum is increased ('Verle, 
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1960). Against speculation about involvement of bradykinin 
in pregnancy and labour, Berde and Saameli (1961) have 
pointed out that the oxytocic activity of bracyki++in is 
much greater in vitro than in vivo. This might be 
explained by kininase activity. More information is 
required before the role of bradykinin in parturition can 
be evaluated. 
Anaphylaxis: 
Only one report on the appearance of bradykinin in 
anaphylaxis is available. Beraldo (1950) collected blood 
from sensitised dogs before and "several minutes" after 
shock, and tested it by direct application to the isolated 
guinea-pig ileum in presence of mepyramine. He reported 
"bradykinin activity" in 7 out of 18 experiments, and in 
some of these samples activity appeared only after 
incubation. This evidence and Beraldo's conclusions are 
discussed later in Part III ( "Discussion "). 
Malaria: 
Recently Tella and Maegraith (1962) have reported a 
decrease in the blood bradykininogen level in monkeys with 
experimental malaria. The aotual amount of bradykinin 
involved is hard to assess because their method involved 
loss of bradykininogen during treatment prior to assay. 
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ANAPHYLAXIS: 
The term anaphylaxis was coined by Portier and 
Richet (1902.) to describe the characteristic and violent 
reactions in animals to substances, not necessarily toxic, 
to which they have previously been sensitised. The 
general picture of anaphylaxis varies from species to 
species, according to the tissue or organ which is most 
affected ( "shock organ "), though changes in other tissues 
also contribute to the overall picture. For example, 
lung is the shock organ in the guinea -pig, and broncho- 
constriction is the cardinal feature of anaphylaxis in this 
animal. 
The steps leading from antigen- antibody reaction to 
these violent events is still not fully understood and 
various theories exist. The humoral theory was the 
earlier thesis to be put forward. It was known that when 
blood was treated with antigen- antibody precipitate in 
vitro, toxic products ( "anaphylatoxin ") were formed, which 
on injection into animals could reproduce the features of 
anaphylaxis. It was therefore postulated that antigen and 
antibody, combining in the blood stream would similarly 
lead to the formation of various toxic products and thus 
produce anaphylactic phenomena. Later findings, however, 
cast serious doubts on this ilea, t. Anaphylatoxin was 
shown to form when serum was treated with not only antigen - 
antibody precipitate, but such non -specific substances as 
peptone, agar and kieselguhr. The necessity of a "lag 
period" before injection of antibodies led to development of 
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passive sensitisation also went against the concept of the 
whole process taking place in the blood stream; in that 
event no lag period would have been necessary. The humoral 
theory as such gradually fell into disfavour and was 
displaced by the "cellular theory" for which there was 
increasing experimental support. This postulates that 
anaphylaxis occurs only when antigen combines with anti- 
bodies fixed on cells. If large amounts of antibody are 
present in circulation, it combines with antigen, thus 
preventing its union with sessile antibodies, and anaphylax- 
is does not oocur. So the relative amounts of antibody in 
blood and tissue would decide whether an immuae or 
anaphylactic response would follow challenge with antigen. 
Enzymatic mechanisms in anaphylaxis: 
Ensymic activity has long been suggested as the 
biochemical mechanism leading to the features of 
anaphylaxis. The earlier concept was that intracellular 
precipitation was followed by digestion with adsorbed 
protease, forming toxic substances like peptone. When 
non -precipitating antibodies were shown to produce 
sensitisation (Kabat and Benacerraf, 19+9; Kuhns and 
Pappenheimer, 1952) this theory became unrealistic. 
The nature of the enzymic mechanisms involved is still a 
subject of controversy. 
Proteolysis: 
The idea of involvement of a proteolytic enzyme is 
quite old, and followed the findings that administration of 
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peptone and other protein degradation products could mimic 
anaphylactic phenomena (Vaughan and Wheeler, 1907; Biedi 
and Kraus, 1909). The earlier theories suggested that 
antigen -antibody precipitate adsorbed protease which acted 
on it to release "anaphylatoxin" (Friedberger, 1909, 1910; 
Friedmann, 1909). It was found later that addition of a 
large amount of non- specific substances could form 
anaphylatoxin. This was interpreted to indicate that a 
delicate balance normally exists between proteolytic and 
anti- proteolytic activity in blood, which can be easily 
upset. Bronfenbrenner (1915) and Jobling and Petersen 
(1914) suggested that anaphylaxis alters this balance, 
probably by reducing the antiprotease activity; this leads 
to a heightened protease activity which in turn produces 
the features of anaphylaxis. 
It was later found that addition of antigen produces 
contraction of isolated sensitised guinea -pig uterus and 
ileum, washed virtually free of blood (Schultz, 1910; 
Dale, 1913). This meant that anaphylactic phenomena could 
take place in the virtual absence of blood or serum. The 
serum activation theory was thus gradually abandoned and 
replaced by the cellular theory with histamine as the central 
causative agent. 
Interest in proteolytic enzymes was revived when Rocha 
e Silva (1939, 1940) showed that intravenous injection of 
trypsin could mimic anaphylactic phenomena. He reported 
( Rocha e Silva, 1943) that compounds of histamine with amino- 
acids were pharmacologically inactive, but activity appeared 
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on hydrolysis, and suggested that histamine was possibly 
bound to free carboxyl groups of proteins by peptide 
linkages. It has been argued, however, that cold 
trichloroacetic acid and other mild hydrolysing agents, 
which do not split peptides in vitro, do release histamine 
in vivo (Scheyer, 1956; McIntire, 1956). 
The modern version of the protease activation theory 
is that antigen- antibody reaction activates normally 
inactive proteases present in tissue or serum or both. 
The enzymes then damage certain specified cells to release 
histamine, 5- hydroxytryptamine, heparin etc., which 
produce the observed response. In addition, the liberated 
enzyme may directly attack vascular endothelium, causing 
further damage (Burdon, 1952) 
Further reports on protease activity in anaphylaxis 
followed, both in vivo and in vitro. Ungar and Mist (19+9) 
had reported that when antigen was added in vitro to cell - 
free sensitised guinea -pig plasma or serum, protease activity 
was increased. Similar reports have been made regarding the 
blood of rabbit and dog (Geiger, 1952; Cliffton, 1952). 
These results were contested by Maclntire, Roth and 
Sproull (1950) who used rabbits. Working in vitro, 
Ungar and Damgaard (1955) found that on challenge 
of sensitised guinea -pig lung, increase in protease 
activity and histamine release followed a parallel course. 
Since protease inhibitors like soya bean inhibitor 
suppressed histamine release, they suggested that 
proteolysis was the basic event which led to histamine 
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release. Hayashi (1956) found increased protease activity 
on addition of antigen in vitro to a culture of monocyte 
cells from rabbit peritoneum. 
In vivo, Lowell, Franklin, Schiller and Follensby(1956) 
have reported raised protease activity in human blood 
during attacks of hay fever. Increased protease activity 
has been reported in the blood, urine (Damgaard and Ungar, 
1952) and lung (Herberts, 1949, 1955a, 1955b, 1958) of 
guinea -pig. 
Some important evidence is now available regarding 
the nature of the enzymes involved in the release of 
histamine during anaphylaxis in guinea -pig lung (Austen 
and Brocklehurst, 1961a). These workers found that 
ester and peptide substrates and several types of the 
inhibitors of chymotrypsin, but not those of trypsin, 
carboxypeptidase or leucine aminopeptidase, inhibited the 
release of histamine. Their results suggest that these 
substances inhibit an antigen- antibody activated step 
because they had no activity if applied beforehand but 
washed out of the tissue before challenge with antigen. 
These workers have suggested that activation of a 
chymotrypsin -like enzyme is necessary for anaphylactic 
release of histamine from guinea -pig lung. In this 
connection, it is interesting to note that rat mast cells 
have been reported to contain trypsin- like (Glenner and 
Cohen, 1960), ohymotrypsin- like (Benditt and Arase, 1959) 
and leucine aminopeptidase -like (Braun -Falco and Salfeld, 
1959) enzymes. 
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While evidence is available on the association of 
anaphylaxis and activation of enzymes, its interpretation is 
still a matter of controversy. Tissue contains a number of 
proteases and other enzymes, and little is known about most 
of them. Part of the confusion in this field is caused by 
equating fibrinolytic or plasmin- like activity with 
protease activity. Proteases vary widely in their 
substrate specificity, and lack of activity on fibrin, 
casein or haemoglobin does not necessarily indicate lack of 
protease activity; it may merely mean that the appropriate 
substrate had not been employed. Furthermore, if an 
active substance has a lytic effect on a particular 
substrate (e.g. fibrin) it does not necessarily follow that 
it is identical with any one particular engyme (e.g. 
plasmin). It should also be remembered that blood contains 
a number of proteases; some exist as precursors, some are 
combined with inactivators. One has only to consider the 
many ways in which clotting can take place to illustrate 
this (Albrechtsen, 1959). 
Non-proteolytic engyme: 
Monger and Schild (1957a, 1957b, 1958) investigated 
the effect of various enzyme inhibitors, oxygen lack, 
calcium lack and other factors on the release in vitro of 
histamine from anaphylactic guinea -pig lung. On the basis 
of their findings, they have put forward the hypothesis of 
an intracellular, heat -labile, oxygen -requiring enzyme 
system which is responsible for the release of histamine 
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and perhaps other pharmacologically active substances. 
They suggested that both free sulphydryl groups and 
disulphide groups are necessary for the anaphylactic 
reaction (Edman, Mongar and Schild, 1961; Mongar and Schild, 
1962). Protein denaturants inactivated the mechanism. 
They found that oxygen lack depressed histamine release. 
The effect of temperature on the lung tissue preparation was 
in keeping with enzymic activation. Mongar and Schild 
(1957) found that calcium was an essential ion for histamine 
release. The effect of pH- alteration also resembled an 
enzyme -pH curve. In the opinion of Mongar and Schild 
(1957a, 1957b, 1958) the postulated enzyme system is not 
proteolytic, though protease activation and histamine 
release could be parallel phenomena. They have pointed 
out that heating above 45 °C inactivates the anaphylactic 
mechanism, but not the proteolytic mechanism. Inhibition 
of anaphylactic histamine release, whether by heat or by 
chemical inhibitors, is accompanied by a potentiation of 
histamine release by organic bases, yet the action of both 
types of releasers lead to proteolysis. These authors 
suggest that proteolysis is a general feature accompanying 
histamine release due to different causes, while the various 
inhibitors they have tested act on a more specific mechanism 
found so far to operate only in anaphylaxis. 
Lecithinase -A hypothesis: 
Uvnás and Thon (1961) have suggested that 
lecithinase is normally present in an inactive form on the 
mast oeil surface. Compound 48/80 and antigen activate 
lecithinase and consequently mast cells are disrupted and 
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histamine is released. This hypothesis was based on their 
findings that lecithinase disrupts rat mast cells. This 
phenomenon, in common with disruption by compound 4.8/80 
or antigen, is inhibited by sulphydryl- blocking agents. 
Other lecithinase- containing agents like snake venom and 
bee venom also release histamine. Furthermore, calcium 
lack inhibits lecithinase activity in vitro (Long and Penny, 
1957) the disruption of mast cells by lecithinase activity 
or antigen challenge in vitro. In view of the suggested 
lipid nature of SRS (Chakravarty and Uvnäs, 1960), a 
mediator in anaphylaxis, this postulation is of much 
potential interest, but the evidence available in support 
so far is not adequate. It is possible, of course, that 
more than one enzyme system is involved in the liberation 
of different mediators of anaphylaxis (Brocklehurst, 1962). 
Pharmacologically active substances in anaphylaxis: 
The anaphylactic response is brought about by 
pharmacologically active substances which are either 
released or formed in tissue as a result of antigen - 
antibody reaction. DLenkin has applied a similar concept 
with respect to tissue reactions in inflammation. Of the 
mediators in anaphylaxis, more information is available 
about histamine than any other. In recent years, 
information has accumulated about SRS -A, 5- hydroxy- 
tryptamine and heparin. A number of other substances 




The possible involvement of histamine as a mediator in 
anaphylaxis was realised when Dale and Laidlaw (1910) 
pointed out that the toxic features of histamine could mimic 
anaphylactic phenomena to a large extent. This was soon 
confirmed by others (Biedl and Kraus, 1909, 1911; Aronson, 
1912). During 1927 -29, the view that antigen- antibody 
reaction releases histamine from tissues, of which it is a 
natural constituent, was clearly formulated. It was 
subsequently shown that histamine is released following 
antigen- antibody reaction in most species - dog, guinea -pig, 
rabbit, cat, cockerel and monkey (Feldberg, 1961). This 
°sours after challenge both in vivo and in vitro. In man, 
histamine is released during attacks of allergy, and on 
challenge in vitro of isolated perfused human bronchial 
chain from allergic patients (Schild, Hawkins, Monger 
and Herxheimer, 1951). Concerning rats, there have been 
contradictory reports. Mota (1957) has reported raised 
blood histamine levels. Isolated tissue fragments of 
sensitised skin and mesentery (Mots and Ishii, 1960) have 
been shown to release histamine; disruptive changes, such 
as occur with histamine liberators have also been reported 
(Mota and Ishii, 1960) in vitro. Brocklehurst (1960) 
did not find any significant histamine release due to 
anaphylactic shock in rat lung, liver or hindquarters; nor 
could the anaphylactic changes in rat mast cells be 
confirmed by Sanyal and West (1958) 
The release of histamine has been taken to indicate 
1+1 
the degree of tissue response to antigen -antibody union and 
much work done to elucidate the chain of events leading 
therefrom to histamine release. A résumé of the contending 
theories has been already given under "enzymic processes 
in anaphylaxis ". 
The role of histamine as the major mediator in most 
species can now be taken as well -established. As 
Feldberg (1961) has pointed out, the trend is now in the 
opposite direction - i.e. to explore phenomena which cannot 
be satisfactorily explained by histamine release. The 
search for other mediators has been fruitful in recent 
years, and good evidence has been obtained about SRS -A, 
5- hydroxytxyptamine and heparin as mediators, apart from 
inconclusive evidence about other proposed mediators. 
SRS-A: 
Kellawgy and Trethew (1938) had found that in per - 
fused anaphylactic guinea -pig lung, a substance appeared 
which produced a slow contraction, thus modifying the 
relaxation phase of the quick contraction of histamine, on 
guinea -pig ileum. In 1938, they had found this substance 
in effluent from lung and liver perfused with snake venom. 
In view of the slow contraction it induced, it was termed 
SRS (Slow Reacting Substance). Brocklehurst (1953 et seq.) 
found that during anaphylaxis in guinea -pig lung in vitro, 
a smooth muscle contracting, mepyramine- resistant, slow 
reacting substance appeared in the effluent. He 
established the separate identity and pharmacological 
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profile of this substance, and, pending identification of 
its chemical nature, named it SRS -A (Slow Reacting 
Substance of Anaphylaxis) to distinguish it from other 
possible slow reacting substances, not necessarily identical 
SRS -A could be distinguished from histamine, acetylcholine, 
5- bydroxytryptamine, bradykinin, substance P, adenosine 
triphosphate and other substances. It was found in 
anaphylactic lung perfusate of rabbit, monkey and allergic 
man also, though not from rat. SRS -A was not found to be 
formed from platelets and other constituents of blood; it 
originates from lung tissue. Unlike histamine, it is not 
released from preformed stores, but formed as a result of 
antigen -antibody reaction in the lung. In guinea -pig 
the substance was found to occur chiefly in the lung and 
vascular tissue. Chemical identification of this substance 
has been rendered difficult by its instability after 
purification: Brocklehurst (1960) has suggested that it 
could be a lipopolysaccharide. Recently Smith (1962) has 
suggested that it is very much akin to methoayneuraminio 
acid, but further proof is required before this can be 
accepted. The intimate mechanism of its release has been a 
matter of controversy. Austen and Brocklehurst (1961) are 
of the opinion that the chain of events leading from 
antigen -antibody reaction to the release of histamine and 
SRS -A must have an early part in common, but the final 
stages are different as shown by the different rates at 
which histamine and SRS -A leave shocked lung. Chakravarty 
(1959) has suggested the same mechanism for the release of 
4-3 
both. The role of mast cells as a source of SRS -A has 
been a matter of controversy. A good correlation between 
the amounts of histamine and released SRS -A would go in 
favour of mast cells as the major source of SRS -A. This is 
difficult to show because of biological variation inherent 
in such experiments, e.g. different levels of sensitivity, 
of tissue content of histamine and SRS -precursor, and 
different rates of diffusion and inactivation of the enzymes 
and pharmacological agents involved. Chakravarty (1960) 
has claimed such a correlation, but his use of litter -mate 
animals introduce a bias in favour of such correlation. 
Bonus and Chakravarty (1960) have also reported a 
correlation between numbers of mast cells involved, and 
amounts of histamine and SRS released. Brocklehurst 
(1962) considers the correlation too poor to support such 
a theory; he has also pointed out that in vitro shock of 
guinea -pig mesentery leads to release of histamine but not 
SRS -A, and so mast cells are unlikely to be a major source 
of SRS -A. Until a suitable and speoific antagonist for 
SRS -A is available, evaluation of its role in anaplylaxis 
will not be complete. However, it has explained a number 
of anaphylactic phenomena which could not be explained with 
histamine alone. Furthermore, it is a very likely 
candidate for the causation of asthmatic bronchoconstriot- 
ion, a probability of great clinical importance. 
5-hydroxytryptamine: 
In recent years, this substance has been investigated 
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with regard to its possible role as a mediator in 
anaphylaxis. The mast cells of rat and mouse contain 
5- hydroxytxyptamine (Benditt, Wong, Arase and Roper, 1955) 
The platelets of rabbit are rich in 5- hydroxytryptamine, 
but those of man, rat or guinea -pig are not (Humphrey and 
Jaques, 1954, 1955). 5- hydroxytryptamine occurs also in 
certain parts of the gastro- intestinal tract and the central 
nervous system. 
5- hydroxytryptamine does not seem to be a mediator in 
anaphylaxis in man (Brocklehurst, 1958), dog (Sanyal and 
West, 1958) and guinea -pig (Herxheimer, 1955; Fink and 
Gardiner, 1956; Wiessbach, Waalkes and Udenfriend, 1957; 
Brocklehurst, 1958a), though Sanyal and West (1958) reported 
the release of a rat uterus contractile substance from 
guinea -pig lung, antagonised by lysergic acid diethylamide. 
Alberty and Sehiede (1953) have reported somewhat similar 
findings. Hawkins and Rosa (1959) reinvestigated earlier 
reports of Campbell and Nicoll (1940), and found that 
release of such oxytocic activity was not necessarily 
confined to anaphylaxis, and could be induced by the 
squeezing effect of histamine bronchoconstriction. In the 
rabbit it has been found that the 5- hydroxytryptamine 
content of anaphylactic plasma rises in the circulating 
blood, but the content in whole blood decreases: this is 
probably due to the trapping and destruction of platelets 
in the pulmonary vascular bed; the pulmonary 5- hydroxy- 
tryptamine content is found to rise (Sanyal and West, 1958; 
Waalkes and Coburn, 1959). The free 5- hydroxytryptamine 
4-5 
found in plasma is probably of platelet origin. The role o 
5- hydroxytryptamine in anaphylaxis in rats and mice is 
contested. While it plays a major role in anaphylactoid 
oedema in rat (Rowley and Benditt, 1956; Parratt and West, 
1956, 1957, 1958; Boepffner and Cerletti, 1958), it plays 
at best only an insignificant role in the increased 
vascular permeability of active and passive cutaneous 
anaphylaxis (Inderbitzin and Craps, 1957; Sanyal and West, 
1958; Broeklehurst, Humphrey and Perry, 1960). Weissbach, 
Waalkes and Udenfriend (1957), however, suggest that since 
comparatively large amounts of the amine, its synthesizing 
and destroying enzyme are present in rat lung, it may have a 
role to play. The role of 5- hydroxytryptamine in mice also 
has been contested. It has been Ida.Q. ri (Fink, 1956) that 
antigenic contraction of sensitised isolated mouse uterus 
can be suppressed by 5- hydroxytryptamine antagonists. 
Weiser (1957) and Fox, Einbinder and Nelson (1958) have 
reported that lysergic acid diethylamide and reserpine 
prevent anaphylactic features in mice mainly attributed to 
histamine.'... 
On the basis of evidence so far available, 5- bydroxy- 
tryptamine plays some part during anaphylaxis in rabbit, 
but adequate evidence is not available to ascribe a role 
firmly to it in other species. 
Heparin: 
Heparin is another pharmacologically active substance 
occurring in mast cells which is known to be liberated in 
anaphylaxis. It was reported to occur in mast cells as 
early as 1937 (Jorpes, Holmgren and Wielander, 1937). 
MacIntosh and Paton (1957) believe that basic histamine in 
mast cells is balanced in charge by the acid heparin which 
explains why the two substances are often released together. 
Eagle, Johnstone and Ravdin (1937) first suggested that 
inooagulability of dog blood during anaphylaxis was due to 
the release of heparin from liver into blood. Jaques and 
Walters (1941) established this view and showed that mast 
cells were the site of origin in the liver. Other workers 
extended these findings to isolated perfused liver later 
(Roche e Silva, Scroggie, Fidler and Jaques, 1949; 
Soroggie and Jaques, 1949). However, incoagulability of 
blood does not occur in rabbit or guinea -pig; the 
coagulation time is slightly prolonged. A metaohromatic 
substance, related to heparin but not an anticoagulant, 
appears in blood. Like heparin, this appears to be 
released together with histamine (Monkhouse, Fidler and 
Barlow, 1952). 
Bradykinin: 
Only one report has been published so far on the 
possible activation of bradykinin in anaphylaxis. Beraldo 
(1950) found that the blood of dogs in anaphylaxis, when 
added to a bath containing an isolated guinea -pig ileum 
could produce a slow contraction in the presence of 
atropine and mepyramine. He concluded that this was due 
to increased bradykinin content of blood. The extent of 
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such increase was found to be quite variable, and some 
post -shock samples needed incubation before any activity 
could be detected: hence he felt that bradykinin was 
unlikely to play any important part in anaphylactic 
response. At that time it was not known that dilution of 
blood in physiological solution, or its exposure to glass 
leads to formation of bradykinin (Schachter, 1956; 
Armstrong, Jepson, Keele and Stewart, 1957) and appropriate 
precautions against activation during experimental 
manipulations were presumably not taken. This makes it 
difficult to interpret Beraldo's findings. A detailed 
discussion and evaluation of these findings is given 
later in Part III under "Discussion ". 
Substance of Campbell and Nicoll: 
In 1936, Ungar and Parrot found that challenge of 
sensitised tissue in an organ bath produced a contraction 
in another suitable unsensitised smooth muscle preparation 
mounted in the same bath. Employing this technique, 
Campbell and Nicoll (1940) found that during anaphylaxis, 
a substance was released from guinea -pig lung which 
contracted rat uterus in vitro. Further information is 
not available about the possible nature of this active 
principle. These workers do not seem to have employed 
lungs washed free of blood, and it is possible that a 
certain amount of blood was present in the preparation. 
Hawkins and Rosa (1959) repeated and interpreted this work 
as mentioned earlier. 
PART II 
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METHODS AND MATERIAL 
lREPARATION OF ANTIGEN: 
Except where mentioned, egg albumin was used as the 
antigen throughout the present experiments. 
Crude egg albumin: 
A freshly -made 10% solution of egg albumin in normal 
saline containing 0.5% phenol was used. After phenol was 
added, the mixture was left at room temperature for an hour 
and any precipitate discarded. 
Crystalline egg albumin: 
1% solution in normal saline was used. This was 
stored at -10 °C. 
Alum- adsorbed egg albumin: 
4.6 ml of N sodium bicarbonate was added to 10 ml of 
10% solution of crude egg albumin in normal saline. A 10% 
aqueous solution of potash alum was added to it dropwise 
while stirring, until the pf came to 6.8 (H.D.H. capillator). 
Evolution of CO 
2 
ceased as this point approached. The 
mixture was kept at 4 °C for 2 -3 hours and centrifuged. 
The precipitate was washed twice in distilled water, and 
finally was suspended in 10 ml phosphate buffer at pH 7.4, 
and stored at 4 °C. 
Freund's adjuvant antigen: 
The emulsion had the composition recommended by 
Dresser (1960), as given below. 
Light liquid paraffin 2 ml 
Heat killed Mycobacterium tuberculosis ¿ mg 
Sorbitol mono- oleate (Grill K 16) 1 ml 
10% egg albumin in normal saline 2 ml 
The solution was squirted through the nozzle of a tuberculin 
syringe until a suitable emulsion was obtained; this did 
not spread when a drop was placed on the surface of 
distilled water. The emulsion was usually used the same 
day, but occasionally stored overnight at 4°C. It was 
warmed to body temperature just before use, and a wide bore 
hypodermic needle was used for injection. 
SENSITISATION OF ANIMALS: 
Guinea -pigs: 
Smooth- haired guinea -pigs of either sex about 3 weeks 
old and approximately of 200 g bodyweight were injected with 
1 ml crude egg albumin solution intraperitoneally and 1 ml 
subcutaneously. The animals were used 21 to 35 days later. 
After four weeks, 2 mg alum -adsorbed antigen in 3 ml normal 
saline was injected intraperitoneally as a booster once 
every 2 -3 weeks. These animals were used 15 to 28 days 
after the last of such injections, which maintained 
sensitisation at a high level. 
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Rabbits: 
Rabbits of either sex of 1.5 to 2.5 kg bodyweight were 
used. 50 mg of antigen in Freund's adjuvant was injected 
subcutaneously and repeated after one week. Six weeks 
later, six intravenous injections of alum -precipitated 
antigen were given at intervals of three days: these were 
graded, rising from 2 mg to 10 mg. The animals were 
employed six to eight days after the last injection. 
ts: 
Albino male rats (listar type) of 100 to 150 g body - 
ight were used. 25 mg of Freund's adjuvant antigen was 
njected subcutaneously and repeated one week later. After 
three weeks, 2 mg antigen was injected intravenously. The 
animals were used two to three weeks later. 
COLLECTION OF BLOOD: 
Guinea -pigs and rats were anaesthetised with urethane 
(1.75 g/kg bodyweight) given partly intraperitonealiy and 
partly subcutaneously. A polythene cannula was tied into 
one common carotid artery for the purpose of bleeding and 
another was tied into the external jugular vein for 
administration of antigen. In the case of rabbits, 
intravenous anaesthesia was induced with sodium pento- 





Virgin albino rats were brought into artificial 
oestrous by a subcutaneous injection of stilboesterol 
(10)4g /100 g bodyweight) in arachis oil: 18-20 hours 
later, the animal was killed, and a section of the uterine 
horn, about 2 on long, was suspended in a 1 or 2 ml 
organ bath containing oxygenated de Jalon's solution at 
30 ° -31 °C. The de Jalon solution contained 10 
-6 
g/ml 
atropine sulphate, and when 5- hydroxytryptamine was to be 
excluded, freshly made 2- bromo- lysergic acid, 2 x 10 -7 
or 5 x 10-7 g/ml.. Bradykinin was usually left in the 
bath for 60 seconds, though in some preparations this had to 
be longer. A cycle of 5 minutes was usually employed. 
The writing lever exerted a load of 300 -400 mg and gave 
a magnification of if to 6. 2 + 2 point assays were 
done only when determining the potency of crude bradykinin 
made from ox plasma in terms of synthetic material or 
Mocha e Silva's Pool I standard, kindly given by 
Professor H.O. Schild of University College, London. 
Otherwise, in view of the comparatively long time -cycle 
and the nature of the experiments, a simple bracketing 
assay was employed (Dale, 1912). Such an assay is shown 
in figure 1. The kymograph was stopped between 
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Fig. 1: Rat uterus: Bracketing assay of extract 
of anaphylactic sample of guinea -pig 
blood (*U) against bradykinin (= BK) . 
Guinea -pig ileum: 
A piece of terminal guinea -pig ileum about 2 cm long, 
was put up in a 1 -2 ml bath at 34° to 35 °C in oxygenated 
Tyrode solution. An exposure of 30 to 45 seconds and a 
cycle of 4 minutes was generally adequate. 
Rat duodenum: 
The proximal 2 -3 cm of duodenum from albino rats of 
120 -150 g bodyweight was suspended in de Jalon solution at 
300-31 °C in an organ bath. The tissue had been stored at 
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oC for two or three hours previously. The lever used 
exerted a tension of 500 mg on the tissue and magnified the 
response 15-20 times. It was found that results were 
better, i.e. the resting tonus was more constant, if the 
tissue was under constant wash by slow overflow. In these 
experiments, the overflow was stopped for 20 to 30 seconds 
before bradykinin was added to the bath. 
RAT BLOOD PRESSURE EXPERIMENTS: 
Albino rats of 150 to 250 g bodyweight were anaesthet- 
ised with sodium barbitone 0.5 g/kg and urethane 0.6 g/kg 
intraperitoneally (Amin, 1953). Blood pressure was 
recorded through a polythene cannula tied into one common 
carotid artery, and leading to a Condon single -limb mercury 
manometer. A. polythene cannula in the external jugular . 
vein was used for administration of drugs or antigen 
dissolved in 0.2 ml saline. 
ISOLATED LUNG PERFUSION: 
This was done according to the method desribed by 
Brocklehurst (1960). The guinea -pig was killed by 
dislocation of the neck; the trachea was at once ligated 
and the lungs with the heart attached were dissected out 
without handling them. An incision was made into the 
right ventricle: through this, a glass- tipped flexible 
cannula was tied into the pulmonary artery, so that the tip 
was proximal to the bifurcation of the pulmonary artery. 
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A similar cannula was tied into the left auricle. The 
preparation was suspended in a water - jacketed chamber at 
37 °C, with the lungs inflated through a tracheal cannula 
to about two- thirds of the in vivo volume. Tyrode 
solution, prewarmed to 37 °C, entered through the pulmonary 
artery cannula, the effluent being collected through the 
left auricular cannula. Blood was flushed out by an 
initial flow of about 20 ml/Min, and the rate was then 
reduced to about 2 ml /min. Collection started only after 
the perfusate appeared to be free from blood. Collected 
perfusate was kept on ice till test ßc1, on the same day. 
PREPARATION OF DOG PSEUDOGLOBULIN SUBSTRATE: 
The method is essentially that of Holdstock et al. 
(1957)and Horton (1958). Healthy adult mongrel dogs were 
anaesthetised with intravenous t _ropeii foìitsodium, and bled 
through a polythene cannula tied into the common carotid 
artery. The blood was collected into a polythene bottle, con- 
taining heparin in a final concentration of 1 I.U. per ml. 
The blood was centrifuged at approximately 900 g for 15 min- 
utes to separate plasma, which was then kept at 56° to 58 °C 
for three hours. The plasma was then subjected to dialysis 
within a viscose cellophane tube (Visking Corporation) at 
4 °C against 10 -20 volumes of distilled water for 36 hours, 
during which the water was changed three times. The plasma 
was treated with ammonium sulphate, and the fractional 
precipitate between 33/ and 46% saturation was separated. 
The precipitate was dissolved in 4..5% NaC1 solution, and 
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dialysed overnight at room temperature against running tap 
water. The solution was taken to pH 2 with hydrochloric 
acid, incubated at 37 °C for 15 minutes, and then brought 
back to pH 7.4.. The material was distributed in ampoules, 
freeze- dried, sealed in dry air and stored at -10°C until 
used. 
PREPARATION OF CRUDE BRADYKININ: 
During the earlier part of the investigation, crude 
bradykinin was used for bioassay purposes. Defibrinated ox 
blood was obtained from the abattoir, and after treatment as 
shown above, the material was suspended in phosphate buffer 
pH 7.4.. This was incubated with trypsin (0.4 mg/ml 
plasma) at 37°C for 20 minutes after which 2 volumes of hot 
ethanol was added to the reaction mixture. The mixture was 
kept in a boiling water bath for five minutes, cooled, and 
dried at 35°C in partial vacuum in the presence of a slow 
stream of nitrogen. The dried material was stored at 
-10 °C. 
MATERIAL: 
Analar grade reagents or the best available were used 
throughout. All solvents were redistilled in glass. 
Water was glass -distilled or deionised in "Elgastat ". 
Crude egg albumin (British Drug House), twice -crystallised 
egg albumin (L. Light & Co.), Grill K 16 ( Croda Ltd., Goole, 
Yorks), Mycobacterium tuberculosis residue from P.P.D. 
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preparation (Veterinary Research Laboratory, New Hall, 
Weybridge, Surrey), magnesium -free trypsin (Armour), salt - 
free chymotrypsin (Armour), soya bean trypsin inhibitor, and 
hexadmethrine bromide (Abbott) were obtained commercially. 
Synthetic bradykinin (Parke Davis & Co.), 2- bromo -lysergic 
acid (Sandoz Ltd.) and mepyramine maleate (May and Baker 
Ltd.) were made available by the manufacturers. 
During some of the earlier experiments, before 
synthetic bradykinin was obtained, crude bradykinin 
prepared as above was used for bioassay. This had been 
quantitated against a standard bradykinin sample of Prof. 
M. Rocha e Silva. Later, synthetic bradykinin was used. 
All amounts of bradykinin mentioned in the present work are 
in terms of the synthetic material. 
Ethanol was redistilled in glass before use. Siliconed 
glassware or polythene was used throughout for the handling 
of blood or plasma. 
R E S U L T S 
SECTION I 
DEVELOPMENT OF METHOD FOR ESTIMATION OF 
BRADYKININ IN BLOOD 
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SECTION I 
ESTIMATION OF BRADYKININ IN BLOOD: 
The study of a possible release of bradykinin in blood 
from its precursor globulin in vitro requires a technique 
which will neither form nor destroy bradykinin. As no 
suitable method was available, experiments described in this 
section were undertaken to develop a suitable method for 
estimation of bradykinin in blood. 
Guinea -pigs, rabbits and rats were bled via a 
polythene cannula from the common carotid artery. Blood 
was permitted to flow out when required, straight into 4 
volumes of glass -distilled ethanol at 2 ° -li. °C. The volume 
of blood collected was found by directly reading off from a 
graduated glass cylinder, or by a graduated polythene 
centrifuge tube. As the blood flowed out, the blood - 
ethanol mixture was gently shaken to avoid, as far as 
possible, formation of large coagula. After collection, 
the mixture was thoroughly shaken to break up any lumps, 
and then centrifuged at 0 ° -4. °C at approximately 3,500 g 
for 20 minutes. The supernatant, a clear fluid which 
often had a pale yellow tinge, was dried under reduced 
pressure at 35 ° -40 °C in a slow stream of nitrogen. The 
dried material was then reconstituted with saline or de 
Jalon solution, usually to the original volume of blood. 
The reconstituted solution was assayed on rat uterus in the 
presence of atropine sulphate, 5 x 10 -7 g/ml, and 2- bromo- 
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lysergic acid 2 to 5 x 10-7 g/ml. 
Recovery tests: 
The efficiency of this procedure was tested by the 
estimation of amounts recovered from known amounts of 
bradykinin added to blood. One aliquot of the sample of 
blood (control) was estimated for natural bradykinin content. 
In the test sample, the added saline solution of bradykinin 
was allowed to drip slowly into the cold ethanol out of a 
siliconed pipette held in such a way that as much as 
possible of the bradykinin came in contact with the blood as 
it ran from the arterial cannula before reaching the 
ethanol. In some experiments mixture was ensured by 
passing the blood and bradykinin together through a 
polythene tube flared into the shape of a small funnel. 
Samples to which bradykinin had been added for subsequent 
recovery both followed and preceded the control sample. 
In some experiments, the blood was collected in polythene 
or siliconed glass test tubes, and the appropriate amount 
withdrawn with a siliconed glass pipette. All samples 
were estimated for bradykinin as described above. The 
results with guinea -pig blood, rat blood and rabbit blood 
are set out in Tables 1, 2 and 3. Some entries in these 
tables show control, values as 4. 3 ng etc. The estimated 
amount in that sample was less than the lowest limit 
detectable under the circumstances of that particular assay, 
e.g. 3 ng/ml. Thus the real control value in these cases 
may be anywhere between zero and the limit of detection. 
This experimental limitation tends to minimize the increase 
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Directly taken into ethanol 
<4.6 32.9 31.6 27.0 5.9 
43.4 57.5 50.7 47.3 10.2 
<5.7 11.5 12.4 6.7 4.8 
45.7 131.4 97.6 91.9 39.5 
Collected in polythene 
13.8 131.4 101.6 87.8 43.6 767. 
25.2 23.0 42.6 17.4 5.6 747° 





Table 1: Recovery of bradykinin added 
to guinea -pig blood 
6o 










11.0 15.0 24.9 13.9 1.1 92. 
c % 
7.5 30.0 37.o 29.5 0.5 98. % 
7.o 45.0 32.4 25.4 19.6 56._.. % 
6.0 60.0 50.0 44.0 16.0 73.:' % 
7.8 33.3 32.4 24.6 8.7 74.: : 
Mean recovery: 78.8 S.E. 7.5 % 
Table 2: Recovery of bradykinin added to rat blood 
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Mean recovery rate: 85.65 S.E. 5.49 % 
Table 3: Recovery of bradykinin added to rabbit blood 
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in bradykinin levels in active anaphylactic samples, and 
any bias so introduced will operate against the conclusion 
that there is a real difference between the control and 
experimental samples, which the results nevertheless show 
quite clearly. 
The recovery levels in all three species appeared to 
be about three-quarters of the amount added. In the 
guinea -pig, polythene -collected blood tended to give a 
higher control value than ethanol -collected blood, but 
recoveries in both groups were di! a similar order. The 
amount of bradykinin lost in the experimental procedure did 
not appear to be an absolute quantity, neither was it 
closely related to the amount added. It may represent 
the quantity trapped within the clot. 
POTASSIUM CONTENT OF EXTRACTED BLOOD: 
Since whole blood instead of plasma had been 
employed for ethanol extraction, K+ values were estimated 
by flame photometry in extracts from blood of guinea -pig, 
rat and rabbit. In guinea-pig blood extracts, the mean K+ 
content per ml blood extracted was 19.8 j:zEq (range 11+ -21); 
in rat blood extract, the mean content was 17, Eq (range 8- 
26), in rabbit, the mean K+ content was 23.1+,uEq/ml (range 
15 -35). The threshold concentration of K+ producing 
contractions in rat uterus was found to vary between 1+ and 
8 ,uEq per ml bath fluid. Therefore, during assay on rat 
uterus, all samples were diluted at least fivefold before 
testing. However, the quick contraction due to K was quite 
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easily distinguished from the much slower contraction 
induced by bradykinin, and no serious potentiation was seen. 
This limitation of the degree of dilution imposes a lower 
limit of detection of bradykinin in blood by this method, 
notably in small samples. Since active samples needed far 
greater dilution than the minimum, there was no problem in 
the assay of those samples. 
isrysCT OF BRADYKININ DEGRADATION PRODUCTS ON SMOOTH MUSCLE 
CONTRACTION PRODUCED Hf BRADYKININ: 
In view of the potentiation which cysteine exerts on 
the smooth muscle contraction produced by bradykinin 
(Picarelli, Henriques and Oliveira, 1962) it was necessary 
to investigate whether bradykinin split products could 
interfere with the assay of bradykinin. Bradykinin 
was incubated for one hour at 37 °C with salt -free 
ohymotrypsin (0.25 mg/ug bradykinin). At the end of 
the incubation, the mixture was boiled for five minutes, 
and the residual amount of bradykinin estimated; this was 
5% or less of the original amount. Addition of this 
degradation product to bradykinin did not produce any 
potentiation, as tested on isolated rat uterus and guinea- 
pig ileum, which could not be satisfactorily explained 
by the residual amounts of bradykinin in the digestion 




BK ng/ml 015 0.2 
SPLIT PRODUCTS 
OF 
BK ng /ml 
0.15 015 015 0.15 0.15 0.2 0.150.2 0.15 0.15 0.15 
6.0 0.5 0.5 0.5 
* IE 
1.0 1.0 1.0 0.5 
Fig. 2: Effect of bradykinin (= BK) -split products on 
bradykinin- induced contractions of rat uterus; 
asterisk ( *) denotes that bradykinin split 
products were added 60 seconds before brady- 
kinin. Note the residual oxytocic activity 
of BK split products, enough to explain 
apparent potentiation of contraction. 
1' 
TIME 
BK ng /ml 5 10 10 5 5 7.5 7.5 5 5 5 
DEGRADATION 10 10 10 50 50 
PRODUCTS 
Fig. 3: Effect of bradykinin (= BK) split products on 
bradykinin -induced contraction of guinea -pig 
ileum. 
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To summarise, the experiments described in this 
section led to an ethanol -extraction method for estimation 
of bradykinin content of blood, avoiding spontaneous 
formation and destruction during experimental manipulation 
as far as possible. The assay of bradykinin is not 
seriously affected by the presence of extracted or 
extraneous material in the samples. 
SECTION II 
RISE IN BLOOD BRADYKININ LEVEL DURING 
ANAPHYLAXIS AND INDIRECT EVIDENCE FROM 
RAT BLOOD PRESSURE EXPERIMENTS 
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BLOOD BRADYKININ LEVELS IN ANAPRYIAXIS: 
The experiments described in this section were 
designed to investigate (a) whether bradykinin level in 
blood rose after anaphylaxis, and if so, (b) what time 
course was followed. Sensitised guinea -pigs, rats and 
rabbits were used. 
GUINEA-PIGS: 
Intraperitoneal challenge: 
2 mg alum- adsorbed antigen suspended in 3 ml 0.9% 
NaCt was injected intraperitoneally. By this means, the 
antigen is only slowly absorbed and shock is prolonged and 
thus not fatal. The animals were bled, and blood 
bradykinin level determined at , 1, 1 and 2 hours after 
challenge. In the control animals 3 ml normal saline was 
injected intraperitoneally 4, 1, 14 or 2 hours before 
bleeding. The blood bradykinin levels in control and 
shocked guinea -pigs is shown in table 4 and figure 4 
illustrates the time -course. 
Each figure in table 4 represents a different 
animal; only one sample was drawn from any one animal in 
case this procedure itself should cause a rise in blood 
bradykinin. No definite evidence is yet available about a 
rise in blood bradykinin following haemorrhagio shock, but 




Bradykinin ng/ml blood 
Time in hours 
Control 0.5 1.0 1.5 2.0 
4:3.6 11.4 40.9 21.7 14.5 
<1.8 18.1 31.4 19.3 5.5 
4:6.0 9.7 48.3 9.7 16.9 




< 5.1 12.8 49.2 16.8 10.3 
I 
1.8 8.3 2.6 3.1 
Table 4: Blood bradykinin level in intraperitoneally 
challenged guinea -pig. Not more than one 
sample was collected from one animal. 
Figure 4 shows that after anaphylactic shock the blood 
bradykinin level rose in 30 minutes; samples withdrawn 
after one hour were found to be the most active. The 
activity appeared to decline by 12 hours, and was down 
almost to control levels by 2 hours. 
Intravenous challenge: 
In view of results obtained from intraperitoneally 
shocked animals, some guinea -pigs were challenged 
intravenously. In order to keep them alive and permit 
















1/2 I 11/2 
HOURS 
Fig. .: Blood bradykinin level in guinea-pig after 
intraperitoneal challenge. 
Vertical bars represent standard error. 
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injected intraperitoneally 45 minutes before they were 
challenged intravenously with 0.2 ml 1% solution of 
crystalline egg albumin. Samples of blood taken before or 
2g or 5 or 10 minutes after shock were estimated for 
bradykinin content. Bradykinin levels at different times 




Bradykinin ng/ml blood 
Time in minutes after shock 
Control 2.5 5.0 10.0 
- 69.6 - 7.4 
< 3 - 3.5 - 
- 39.0 - 4.4 
- 24.2 - 9.5 
- 51.4 - 16.9 
< 3 - 4.2 - 
<3 - 6.1 - 
- 85.9 20.5 - 
- 40.5 16.2 - 
<3- 51.8 10.1 9.5 
9.2 3.5 2.7 
Table 5: Blood bradykinin levels in mepyramine- 
protected guinea -pigs challenged with 
soluble antigen given intravenously; 
each horizontal row represents one 
animal. 
Each horizontal row in table 5 represents the same animal. 
Not more than two samples were taken from any one animal, 















- - - - - - - - - - - - - - - _ r 
2 1/2 5 
Minutes 
IO 
Fig. 5: Blood bradykinin level in guinea -pig 
after intravenous challenge; vertical 
bars represent standard error 
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level in the later samples. It appeared that the samples 
were most active 2i minutes after shock, but activity 
decreased rapidly, and had almost returned to control 
levels by the end of ten minutes. 
RATS: 
Sensitised rats were challenged intravenously with 
2 mg crystalline egg albumin in 0.2 ml normal saline. 
Samples of blood were obtained before and 5, 10 and 20 
minutes after shock for estimation of bradykinin content. 
The bradykinin levels are shown in table 6, and the time 
course can be followed from figure 6. 
Mean 
S.E. 
Bradykinin ng/ml blood 
Time in minutes 
Control 5 10 20 
< 6 37.7 
< 6 48.3 
< 4.8 133.2 
< 1.2 79.7 11.0 
14.5 108.7 73.6 28.0 
5.7 7.3 
2.5 21.2 5.7 
< 0.5 7.2 
< 5.1 71.5 21 
17.7 13.2 
















Fig. 6: Blood bradykinin level in rat after intravenous 
challenge. 
Vertical bars represent standard error. 
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Each horizontal row represents one animal. Most animals 
were bled only twice. It was found that when two control 
samples of blood (1 -2 ml each) were withdrawn from an 
unsensitised animal, at five minutes interval, the 
bradykinin content of the later sample was not appreciably 
higher than that of the first one. The sample withdrawn 5 
minutes after shock appeared to be the most active: after 
this, the level gradually decreased. 
RABBIT: 
Sensitised rabbits were first bled for a control sample 
2 mg crystalline egg albumin was then injected intravenously 
Wore, ore, an.á. 
to induce shock. Animals were then bled for samplesnat 5, 
10,. and 20 minutes after shock, and blood bradykinin 
levels determined. These blood levels have been tabulated 
in table 7, and figure 7 shows the time course. 
Mean 
S.E. 
Bradykinin ng/ml blood 
Time in minutes after challenge 
Control 5 10 20 
1.5 31.1 12.9 10.4 
<1.0 6.2 1.8 <0.3 
<1.4 6.7 6.4 4.9 
<1.5 9.2 4.0 <2.2 
< 1.3 13.3 6.3 4.4 
5.9 2.4 1.9 















Fig. 7: Blood bradykinin level in rabbit after 
intravenous challenge. 
Vertical bars represent standard error. 
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As in the rat, the 5 minute sample appeared to be the most 
active, after which activity gradually decreased. In 
general, the level of peak activity in rabbit was less than 
in guinea -pig and rat. 
Further efforts were made to identify the active 
principle present in the blood extracts as bradykinin. 
Chymotrypsin digestion: 
Active samples of extracted guinea -pig, rat and rabbit 
blood collected during anaphylactic shock were incubated 
with salt -free cr;ymotrypsin (0.5 mg/ml blood) for 30 
minutes at 37 °C. The reaction mixture was then boiled for 
a few minutes and cooled. The ohymotrypsin, so treated, 
and present in amounts in which it occurred in the reaction 
mixture did not have any oxytocic activity on the isolated 
rat uterus preparation. In all three species it was 
found that chymotrypsin digestion destroyed more than 80% 
of the activity in the extracted sample. This is 
¡illustrated in tracings shown in figures 8, 9 and 10. 
Parallel quantitative assay: 
Extracts of active samples of blood drawn from all 
three species were assayed against bradykinin on rat 
uterus, guinea -pig ileum and rat duodenum. These are 
shown in table 8. The values obtained with different 
test preparations are in reasonable agreement. The 
highest index of discrimination, as described by Gaddum 
(1955) was 2.0. It was important to employ rat 
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duodenum from a qualitative point of view since bradykinin 
relaxes rat duodenum, while almost all other smooth muscle 




Bradykinin ng/ml blood as 























Table 8: Parallel quantitative estimation of active 
samples compared with synthetic bradykinin 
on different test objects. 
The effect of active guinea -pig blood extract on the 
blood pressure of normal rat was noted. The rat was made 
resistant to the Iypotensive effect of histamine and 
5- hydroxytryptamine with mepyramine (20 mg/kg) and 2- bromo- 
lysergic acid (2.5 mg/kg). Intravenous administration of 
the extract produced fall in blood pressure. However, as 
much as 1.5 ml extract had to be administered to produce 
this effect, and so further quantitative examination was no 
done. The large amount of extract needed for lowering 
blood pressure was not surprising in view of the fact that 
about 100 ng bradykinin was needed to produce a hypotensive 












Fig. 8: Rat uterus: Loss of activity on chymotrypsin- 
digestion ( =UC) of extract from guinea -pig 
blood ( =U) collected one hour after intra- 
peritoneal challenge. BK = bradykinin. 
TIME 




Fig. 9: Rat uterus: Loss of activity on chymotrypsin- 
digestion (= UC) of extract from rat blood 
( =U) collected five minutes after intravenous 









Fig. 10: Rat uterus: Loss of activity on chymotrypsin 
digestion ( =UC) of extract from rabbit blood 
( =U) collected five minutes after intravenous 
challenge. BK = bradykinin. 
1' 
TIME 






Fig. 11(a): Relaxation of rat duodenum with extract 
( =U) of post -shock blood from guinea- 























Fig. 11(b) and (c): Relaxation of rat duodenum with 
extract ( =U) of post -shock blood: (b) from 
rat, extract dissolved in 1.25 vols de Jalon 
solution; (c) from rabbit, ITC = chymotrypsin- 
digested rabbit blood extract. 
BK = bradykinin. 
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RAT BLOOD PRESSURE EXPERIMENTS: 
Sensitised rats were prepared for blood pressure 
recording and mepyramine maleate (15 to 25 mg/kg) and 
2- bromo- lysergic acid (2 to 2.5 mg/kg) were given until 
the hypotensive responses to 2 or 3 times the previously 
effective dose of histamine and 5-hydroxytryptamine was 
completely suppressed. It was necessary to administer 
these drugs, particularly 2- bromo- lysergic acid in divided.. 
doses, as otherwise a severe fall of blood pressure follow- 
ed by death occurred. Even with divided doses, there was 
slight lowering in the blood pressure level. Bradykinin 
produced a temporary fall of blood pressure in these 
animals. Intravenous injections of 2 mg crystalline egg 
albumin in 0.2 ml normal saline produced a fall in blood 
pressure, which was prolonged in almost all instances, and 
sometimes resulted in death: in one instance however 
(figure 12) it returned to normal in a comparatively short 
period. Blood pressure records from experiments showing 
the more usual type of response are shown in figure 13. 
To summarise, experiments in this section showed that 
the bracykinin level in blood rose following anaphylaxis in 
guinea -pig, rabbit and rat, and the time -course in these 
species was studied. The identity of the active material 
was confirmed by chymotrypsin digestion and parallel 
quantitative assay. Indirect evidence from rat blood 
pressure experiments supported the conclusion that brady- 





















H S 1 H' S' B 
Mep.+BOL 
B' Ag 
Fig. 13(b): Anaphylactic hypotension in rat after the 
effect of histamine and 5- hydroxytryptamine 
has been excluded. Ag = crystalline egg 
albumin antigen 2 mg; H, H' = histamine 
base 20 and 60 dug /kg respectively; S, Si = 
5- hydroxytryptamine base 4 and 10 pg /kg 
respectively; Mep. + BOL = mepyramine 
maleate 20 mg /kg and 2 bromo- lysergic acid 
2.3 mg/kg respectively in divided doses over 
an interval of 2 hours; B, B' = bradykinin 
0.6 and 1.2,ug/kg respectively. 
SECTION III 
EFFECT OF ANAPHYLACTIC SHOCK ON 
BRADYKININOGEN LEVEL IN PLASMA 
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EFFECT OF ANAPHYLACTIC SHOCK ON BRADYKININOGEN LEVEL 
IN PLASMA: 
Raised blood bradykinin levels during anaphylaxis 
in vivo suggested a concurrent depletion of blood bradykin- 
inogen content. The experiments in this section were 
designed to find out a suitable method for the evaluation of 
bradykininogen in blood, and to detect possible change. It 
is not possible to expresa bradykininogen content of plasma 
in terms of its weight as the material has never been 
obtained pure. Furthermore, the basis of quantitation is 
biological assay of the bradykinin which can be obtained 
from precursor. amounts bradykinin 
obtained by trypsin digestion from 1 ml plasma have been 
accepted as the meaningful indication of bradykininogen 
levels. 
Development of a suitable bradykininogen assay method for 
small samples of plasma: 
A method for estimation of the bradykininogen content 
of small volumes of blood had to be evolved before changes 
due to anaphylaxis could be studied. Two procedures were 
available: (1) The use of fresh plasma as substrate with 
trypsin: A few experiments showed that yields were very 
low with this method, less than 0.25 pg bradykinin per ml 
plasma. The low yield was surmised to be due to 
interfering enzymic activity resulting in spontaneous 
formation and destruction of bradykinin. (2) Initial 
Fig. 12: .Anaphylactic hypotension in rat after the exclusion 
of histamine and 5- hydroxytryptamine. The rat had 
been given 15 mg/kg mepyramine maleate and 2 mg/kg 
2- bromo- lysergic acid. H = histamine base 67 
dag /kg; S = 5- hydroxytryptamine base 2 fig/kg; 
B, B' = bradykinin 0.09 and 0.18pg/kg respectively; 
A = 2 mg crystalline egg albumin antigen. 
Fig. 13(a): Anaphylactic hypotension in rat after the effect 
of histamine and 5- hydroxytryptamine has been 
excluded by previous administration of mepyramine 
maleate (25 mg/kg) and 2- bromo- lysergic acid 
(2.5 mg /kg); H = histamine base 50)ug/kg; 
S = 5- hydroxytryptamine base 5pg/kg; 
B, B' = bradykinin 1.0 and 0.6pug/kg respectively; 
Ag = crystalline egg albumin antigen 2 mg. 
(Facing p. 81) 
814. 
denaturation with ammonium sulphate, as described by 
Holdstock, Mathias and Schachter (1957), to prevent such 
enzymic interference. This method could not be adopted 
because comparatively large amounts were needed, and the 
experimental manipulations including dialysis were likely to 
lead to bradykininogen loss. 
A simple procedure suitable for small samples, and not 
involving dialysis was sought. The method described below, 
based on denaturation with ethanol was found suitable. 
Arterial blood was collected from sensitised guinea - 
pigs via a polythene cannula into siliconed glass 
centrifuge tubes containing heparin (1 I.U. /ml). Plasma 
was separated by centrifugation and added to 4 volumes of 
ethanol at 2 °C being vigorously mixed to give a fine 
precipitate. The mixture was heated at 80 -90 °C for 20 min- 
utes and centrifuged at about 1,300 g and the supernatant 
drained off and discarded; the precipitate was washed in 
distilled water. The precipitate was then suspended in 2 ml 
0.1 M phosphate buffer at pH 7.4, and incubated with trypsin 
(= 0.5 mg/ml plasma) at 37 °C for 20 minutes. After 20 min- 
utes, 2 volumes of hot ethanol was added to the reaction 
mixture, and the vessel was kept in a boiling water bath for 
a few minutes. It was then cooled and centrifuged for 20 
minutes approximately at 1,300 g. The supernatant was 
o 
dried in partial vacuum at 350-4Ó C in a slow stream of 
nitrogen. The dried material was dissolved in de Jalon 
solution and assayed on rat uterus for bradykinin content. 
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Changes in plasma bradykininogen level before and after 
anaphylaxis: 
After collection of a 1 -2 ml control sample of blood 
from sensitised guinea -pigs, 2 mg aluminium- hydroxide- 
adsorbed antigen in 3 ml saline was injected intraperiton- 
eally. Three hours later, another sample of blood was taken. 
Bradykininogen content in each sample was estimated accord- 
ing to the procedure described above. Since the rise in 
blood bradykinin level practically disappears after two 
hours, it was felt that by three hours, bradykinin formation 
would have ceased. In three animals, in addition to samples 
for bradykininogen estimation, a sample of blood was obtain 
one hour after challenge so as to relate the peak blood 
bradykinin level to the bradykininogen depletion in those 
animals. The results are shown in table 9 and figure14; 
Mean 
S.E. 
Bradykininogen ! bradykinin 










8.4 4.17 4.23 50.3 
8.79 4.45 4.34 49.4 
5.2 4.97 0.23 4.6 
6.9 3.35 3.55 51.4 
8.86 5.87 2.99 33.7 37.0 
13,89 7.2 6.69 48.1 61.7 
18.75 10.12 8.63 46.0 93.7 
19.1 8.9 10.2 53.4 
23.0 10.1 12.9 56.1 
15.72 11.21 4.51 28.7 
12.86 7.03 5.83 42.2 
1.92 0.91 1.12 5.0 
Table 9: Bradykininogen content in guinea -pig plasma 









Fig. 11+: Depletion of plasma bradykininogen 
after retarded shock. The vertical 
bar represents standard error 
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it will be seen that in three hours after shock, the blood 
was considerably depleted of bradykininogen. Furthermore, 
the level of blood bradykinin at the expected peak period 
(one hour after shock) bore a rough relationship to the 
degree of bradykininogen depletion. 
In two experiments fresh plasma was used as substrate, 
and the results are shown in table 10, mainly to illustrate 
the remarkable difference in bradykininogen yield by the 
different methods. 
Bradykininogen levelpg/ml plasma 
expressed as = bradykinin 




Died in less than 
three hours 
Table 10: Bradykininogen estimation by using direct 
digestion of plasma with trypsin 
To summarise, experiments in this section led to a 
satisfactory method for bradykininogen assay in small 
samples; employing this method, anaphylactic shock was 
shown to deplete blood bradykininogen level considerably. 
SECTION IV 
FÜRTIER EXPERIMENTS ON BRADYKININ FORMATION: 
(1) ANTIGEN - ANTIBODY REACTION IN BLOOD IN VITRO, 
and 
(2) ANTIGEN -ANTIBODY REACTION IN PERITONEAL 
FLUID IN VIVO. 
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FURTHER EXPERIMENTS ON BRADKININ FORMATION: 
(1) ANTIGEN -ANTIBODY REACTION IN BLOOD 
IN VITRO, AND (2) ANTIGEN- ANTIBODY 
REACTION IN PERITONEAL FLUID IN VIVO 
The experiments described in Section II showed a 
raised level of bradykinin in the circulating blood during 
anaphylaxis in vivo. The experiments in this section were 
designed to show if blood contained all the factors 
necessary for the production of bradykinin during 
anaphylaxis, and if bradykinin was detectable elsewhere. 
Blood was collected from sensitised guinea -pigs and 
rats via a polythene arterial cannule in polythene contain- 
ers containing heparin (final concentration in mixture 1 
I.U. /ml blood). Blood was handled throughout with 
polythene or siliconed glassware. 2 ml aliquots of blood 
were incubated with 0.2 ml normal saline as control or with 
2 mg crystalline egg albumin in 0.2 ml saline. Guinea -pig 
blood was incubated for two minutes and rat blood for five 
minutes. After incubation, control and experimental 
samples were immediately mixed with ethanol, as described 
in section I and estimated for bradykinin content. The 
estimated levels are given in tables 11 and 12 which show 
that the challenged and control samples of blood contained 
virtually the same insignificant amount of bradykinin. 
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Table 11: Bradykinin level in sensitised guinea -pig 
blood challenged in vitro 











Table 12: Bradykinin level in sensitised rat blood 
challenged in vitro 
Antigen- antibody reaction in the peritoneal cavity of rat 
according to the method of Rapp (1962) followed by 
biological assay of the peritoneal fluid: 
Male rats (100 to 200 g bodyweight) were injected 
intraperitoneally with 0.6 pg anti -BSA antibody in 0.2 ml 
saline or Tyrode solution. Four hours later, 2 mg 
antigen in 5-7 ml of normal saline or Tyrode was injected 
intraperitoneally. The rat was killed ten minutes later, 
and the peritoneal fluid recovered by means of a polythene 
pipette. For control purposes, some animals were 
injected 
with antibody only, but no antigen; some others 
were 
injected with antigen only, but no antibody. 
The 
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recovered peritoneal fluid was kept on ice until estimated 
for bradykinin -like activity on rat uterus the same day. 
The estimated bradykinin content in these samples is shown 
in table 13. It is to be noticed that while antigen - 
antibody reaction was followed by bradykinin -like activity 
in the peritoneal fluid, similar activity was found in 








Saline + + 97.6 
Saline + + 4.8.0 
Saline + - 65.1 
Saline - + 31.6 
Tyrode + - 14.2 
Tyrode - + 18.3 
Tyrode + + 16.8 
Tyrode + + 45.0 
Table 13: Bradykinin -like activity in peritoneal 
fluid in rats following antigen- antibody 
reaction. 
To summarise, experiments described in this section 
showed practically no change in the bradykinin content of 
sensitised blood challenged in vitro; and no significant 
increase in bradykinin -like activity in rat peritoneal 
fluid after anaphylaxis. 
SECTION V 
BRADYmININ- FORMING ACTIVITY DURING ANAPHYLAXIS 
IN VITRO: SENSITISED GUINEA -PIG SKIN 
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BRADYKININ- FORMING ACTIVITY IN GUINEA -PIG SKIN 
PER USATE AFTER ANAPHYLAXIS 
These experiments were done to ascertain whether 
bradykinin might be formed in skin during anaphylaxis in 
vitro. 
Development of a suitable skin perfusion method: 
The existing method of Feldberg and Paton (1951) 
involved thermooautery and thus probably activates 
proteolytic enzymes of the skin. It was therefore 
considered unsuitable, and a method was sought which would 
avoid activation of proteolytic enzymes as far as possible. 
The procedure described below was found to be 
satisfactory. This was based on arterial perfusion of an 
isolated piece of skin from the hip, suspended in air in a 
warm chamber. The effluent flows out of the cut edges of 
the skin, and is collected. 
Sensitised guinea -pigs of 400 to 500 g bodyweight were 
used. The lower half of the body was shaved with electric 
clippers. Under urethane anaesthesia, a vertical 
incision was made from the inguinal ligament downwards along 
the centre of the anterior aspect of the thigh. The 
femoral artery and its profunda femoris branch were 
carefully dissected. All branches of the femoral artery 
except the superficial circumflex iliac artery were 
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divided between ligatures. Particular care was taken 
not to miss any cutaneous or muscular branches. The 
femoral artery was divided between ligatures at a point 
approximately 5 to 10 mm distal to the origin of the 
profunda femoris artery. Through a nick in the profunda 
fomeris artery, a polythene eannula was pushed upwards 
and tied so that its tip was just distal to the origin 
of the superficial circumflex iliac artery(see figure 15). 
The femoral artery was divided between ligatures just 
above the origin of the superficial circumflex iliac 
artery. The area of skin supplied by the superficial 
circumflex femoral artery was excised along with its 
vascular supply. It comprises of an area of 7 to 12 om 
extending over the posterolateral aspect of the upper 
quarter of the thigh. The whole preparation was 
suspended by a thread in a chamber at 37 °C. The isolated 
piece of skin was perfused with Tyrode at 37 °C under a 
pressure head of 150 cm. The effluent from the out 
edges of the skin was collected only after the perfusate 
appeared to be free of blood. The entire perfusion 
assembly is represented diagrammatically in figure 16. 
Blood -free and adequately perfused preparations could be 
obtained by this method, as tested with India ink 
injection following perfusion (see figure 17) . (* vide 
P. 100, at the end of this section, for an alternative 
























Fig. 16: Assembly for guinea -pig 
skin perfusion 
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(a) (b) (c) 
Figure 17: Isolated skin preparation: (a) unperfused; 
(b) from the other limb of the 
same animal; (c) India ink injected after 
perfusion. 
Experimental: 
Effluent was collected over one -minute periods before 
and at various periods after anaphylactic shock. Anaphylax- 
is in vitro was induced by injecting 2 mg crystalline egg 
albumin in 0.2 ml Tyrode or saline at 37°C into the 
perfusing solution just before it reaches the preparation. 
Neither control nor post -shock samples showed any 
braâykinin -like activity, when tested on rat uterus. 
Some samples of perfusate collected in the first minute 
after shock, showed some oxytocic activity in concentrations 
as high as twofold dilution. This would represent 
about 1 ng bradykinin in the entire sample and 
can be ignored. To test for bradykinin- forming 
Fig. 18: Optimum period of incubation of post -shock skin 
perfusate with pseudoglobulin substrate: Rat 
uterus, auxotonic lever; perfusate collected 
over 75 seconds after shock and made up to 4.5 
ml with Tyrode and incubated with 0.5 ml 
substrate. Dilution of aliquots (= x 20) 
drawn at different times shown in illustration. 
SC = control perfusate + substrate incubated 
for 10 mins and S = substrate, both diluted 
x 20. BK = bradykinin. 
(Facing p. 96) 
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activity, the perfusate was incubated at 37 °C with heated 
dog plasma pseudoglobulin solution equivalent to 0.5 ml 
plasma. Preliminary experiments were carried out to 
investigate the effect of varying incubation periods. It 
was found that the optimum incubation period for bradykinin- 
formation was about 10 minutes; activity gradually 
declined after this period, until at 20 minutes the 




BK ng / ml 
1 2.5 5 7.5 10 15 20 
2.5 0.25 
Control perfusates and perfusate samples collected from 
0 to 1, 1 to 2, 2 to 3, 3 to 4., and 4. to 6 minutes were 
incubated at 37 °C for 10 minutes with 0.5 ml dog plasma 
pseudoglobulin. These results (table 14. and figure 19) 
show a rapid and considerable rise or bradykinin- forming 
capacity after shock. This effect disappeared In about 
five minutes. The first minute after challenge was the 
most active period. In one experiment where half- minute 
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samples were collected, the activity was greatest during 
the latter half of the first minute. 
Time in minutes 
Control 0 -1 1 -2 2 -3 3-4 4 -6 
14..0 111* 21 8 20 21 
6 112 35 18 16 11 
72 429 302 234 315 193 
30 272 148 53 42 39 
118 664 437 208 186 162 
Table 14: Bradykinin- forming activity in isolated 
skin perfusate. Antigen was added at 
time 0. 
* = the output was 43 ng in the first 
half -minute and 68 ng in the next 
half- minute. 
As a control the same procedure was followed using 
unsensitised animals (table 15 and figure 20) and in other 
experiments sensitised animals were employed, but instead of 
antigen, histamine acid phosphate (a 5 )4g histamine base) 
was administered. 
Time in minutes 
Control 0 - 1 1 - 2 2 -3 3 -4 4 -6 
Unsensitised skin, antigen added: 
34 1 41 13 33 1 
3 ` 6 5 10 
Sensitised skin, histamine added: 
25 37 38 25 





Table 15: Bradykinin- forming capacity in isolated 
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Fig. 19: Bradykinin- forming activity in guinea -pig skin 




unsensitised + antigen 
sensitised + histamine 
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Fig. 20: Control experiments: estimation 
of bradykinin -forming activity 
in guinea -pig skin perfusate 
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These experiments were done to find out whether increased 
bradykinin -forming capacity could be induced by possible 
mechanical contractile effect of histamine released by 
anaphylaxis. Raised bradykinin- forming capacity could not 
be detected in either unsensitised or histamine -treated 
preparations. 
To summarise, a method was devised for the perfusion of 
isolated skin with minimum activation of proteolytic enzymes. 
Employing this method, it was shown that anaphylaxis in vitr4 
was rapidly followed by increased bradykinin- forming capacity 
in perfusate. This effect could not be reproduced in 
unsensitised animals with antigen or in sensitised animals 
with histamine, and is presumed to come from the cells of th 
tissue as a consequence of antigen -antibody reaction. 
Note on alternate skin area for dissection as mentioned 
in p. 92: 
* Other, though less convenient methods are also feasible 
The cannulation of the same vessel could also be done 
through the external iliac artery; the approach was intra- 
abdominal, and vascular isolation was more difficult. 
Another area of the skin over the anterolateral aspect of 
the lower half of the thorax is also suitable for perfusion. 
In this case, the cannula, tied into the axillary or 
brachial artery, perfuses the branch of the brachial artery 
supplying the area concerned. These vessels, however, 
are 
more fragile and less suitable than the superficial 
circumflex iliac artery. 
SECTION VI 
BRADYKININ FORMATION DURING .ANAPHYLAXIS 
IN SENSITISED GUINEA -PIG LUNG. 
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BRADYKININ FORMATION DURING ANAPHYLAXIS 
IN SENSITISED GUINEA -PIG LUNG 
The experiments described in this section were carried 
out to study the possible role of the lungs in the formation 
of bradykinin during anaphylaxis in guinea -pig. 
Perfusion of blood -free sensitised lungs was carried 
out as described under "Methods and Material ". Anaphylaxis 
was induced by adding 2 mg crystalline egg albumin in 0.2 
ml warm saline to the perfusion fluid as it entered the 
lung.: ' ' The colle cted perfusate was kept at 4. °C 
until used the same day. 
When perfusate collected before and after anaphylaxis 
was tested on rat uterus, no significant activity was seen 
in either. Occasionally, perfusate collected over the 
first minute after shock contracted the rat uterus only at 
concentrations as high as x 2 dilution in the organ bath. 
In such cases, the bradykinin-like activity in the entire 
sample was of the order of 1 ng, and this was held to be 
insignificant. 
The absence of bradykinin in the perfusate from a 
blood -free organ did not exclude the presence of bradykinin 
forming activity. This was investigated by incubating 
the perfusate with pseudoglobulin. Perfusate obtained 
during the two minutes before shook, and periods during 
0-1, 1 -2, 2 -3 and 3-4 minutes after shock were incubated 
with heated dog plasma pseudoglobulin equivalent to 0.5 ml 
plasma, in 0.5 ml saline. After incubation at 37 °C, the 
mixture was placed in a boiling water bath for 4. or 5 
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minutes to stop the reaction, cooled and stored at -10 °C 
until assayed on rat uterus. 
The optimum period of incubation of the reaction 
mixture was first examined by withdrawing aliquots from the 
incubation mixture at different times. The amount of 
bradykinin present was maximum at 10-15 minutes, after 




DILUTION 5 30 30 30 30 45 45 30 30 
BK ng /ml 0.25 0.5 
C S 
0 10' 2.5' 5' 7.5' 10' 15' 20' 10' 
Fig. 21: Optimum period of incubation of post -shock 
lung perfusate with pseudoglobulin substrate: 
Rat uterus; dilutions of aliquots drawn at 
different intervals shown. C = control 
(not incubated); S = substrate; BK= 
bradykinin. 
Substrate incubated in Tyrode, as a control, contained 
some bradykinin; this was taken into account when 
calculating the amount of bradykinin formed by the various 
samples. The amount of bradykinin formed on incubation 
for 10 minutes was calculated for control samples, as well 
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as samples collected between 0-1, 1 -2, 2 -3 and 3-4 minutes 
after anaphylaxis are shown in table 16 and figure 22. 
Time in minutes 
Control 0 -1 1 -2 2 -3 3 -4 
12 48 17 18 8 
12 61 8 0 1 
14 48 11 1 3 
25 66 17 13 14 
Table 16: Bradykinin- forming capacity of isolated lung 
perfusate; antigen was added at 0 minute. 
It is evident that there is a sharp rise in the bradykinin- 
forming capacity of the perfusate in the first minute after 
shock, and a return to control level after 273 minutes. 
For control, similar experiments were done with 
antigen in lungs from unsensitised animals; furthermore, 
in order to investigate whether these results were due to 
the mechanical effects of bronchoconstriction, 10 pg 
histamine instead of antigen was injected into sensitised 
perfused lung. Neither kind of experiment showed a rise 
in bradykinin- forming activity, as can be seen from table 17 
and figure 23. 
Time in minutes 
Control 0 - 1 1 - 2 2 -3 
Unsensitised lung, antigen added 
7 3 3 7 6 
11 13 5 11 11 
Sensitised lung, histamine added 
3 3 3 5 3 
9 5 4 4 4. 
Table 17: Bradykinin- forming capacity in perfusate 














Fig. 22: Bradykinin- forming activity in guinea -pig lung 




unsensitised + antigen 








Fig. 23: Control experiments: estimation 
of bradykinin- forming activity 
in guinea -pig lung perfusate 
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Comparison of bradykinin- forming activity with histamine 
release: 
In three experiments, sensitised lungs were perfused, 
and perfusate collected for 75 seconds before and after 
shock. These samples were estimated for both bradykinin- 
forming activity and histamine content to find out whether 
there was any relationship between the two. The results 
are shown in table 18. The sample with the greatest 
bradykinin- forming activity also contained the largest 




























Table 18: Anaphylaxis in isolated lung perfusion; 
comparison of bradykinin- forming activity 
with histamine release. 
Time -course with fresh guinea -pig plasma as substrate: 
In order to correlate the findings in vitro described 
in this section with the course of events in vivo in guinea- 
pig, post -shock lung perfusate was incubated in polythene 
for different periods at 37 °C with heparinised non- activated 
guinea -pig plasma as substrate (fig. 23A). It was found 
that the amount of bradykinin was highest after 2 -3 
minutes. 
Fig. 23A: Optimum period of incubation of post -shock lung 
perfusate with fresh guinea -pig plasma. All 
incubation samples diluted x 15. BK = brady- 
kinin; P3 = plasma incubated for 3 minutes; 
PC3 = plasma + control perfusate incubated for 
3 minutes. 
(Facing p. 107) 
TIME 







To summarise, experiments described in this section 
showed that anaphylaxis in guinea -pig lung in vitro is 
followed by a rapid and short -lived rise in bradykinin- 
forming activity in the perfusate. These effects could not 
be reproduced with antigen in unsensitised animals or with 
histamine in sensitised animals. The speed of bradykinin 
formation by the post -shock perfusate, when fresh guinea- 
pig plasma is used as substrate, is in accord with the time 
course of anaphylaxis in vivo. There appears to be some 
correspondence between the release of histamine and 
bradykinin- forming activity after shock. 
SECTION VII 
INVESTIGATION OF THE NATURE OF THE 
BRADYKININ- FORMING ACTIVITY OF 
ANAPHYLACTIC GUINEA -PIG 
LUNG PERFUSATE 
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INVESTIGATION OF THE NATURE OF ACTIVITY OF 
ANAPHYLACTIC GUINEA -PIG LUNG FERFUSATE 
The experiments described in this section were done to 
find out the effect, on the bradykinin -forming. activity in 
anaphylactic lung perfusatelof: (a) Heat, (b) pH, 
(c) ethylenediamine tetra -acetic acid, (d) soya bean 
trypsin inhibitor, and (e) hexadimethrine bromide. 
In these experiments, the post -shock perfusate was 
usually collected for 75 seconds commencing 10 seconds 
after administration of antigen, and aliquots (usually 1 
ml) of treated or untreated perfusate were compared. 
Sometimes, when several aliquots were required, samples 
from two or three animals were pooled. 
Heat: 
Aliquots were drawn from the same sample, one was kept 
untreated (as control); others were heated at 56 °C for 30 
or 60 minutes, or at 100 °C for 2 -, 5, 10, 15 or 30 minutes, 
cooled, and then incubated with substrate for 10 minutes. 
The bradykinin formed was estimated on rat uterus. 
These 
results are shown in table 19. At 56 °C more than 
half of 
the activity disappears after 60 minutes, 
whilst at 100 °C 
some loss of activity is evident after five minutes 
and 




reduction in activity, taking 
unheated sample as 10 
Duration of heating in minutes 
2 5 10 15 30 60 
100° 13.5 30 44.8 82.1 90.1 
100° 96.0 96.1 
56° 35.6 58.1 
Table 19: Effect of heat on bradykinin- forming 
activity in post -shock lung perfusate. 
pH: 
Equal aliquots of perfusate substrate mixture were 
b+uf f er 
adjusted -with 0.06 M trishydroxymethylaminomethane ( "tris"), o 
pH values between 5.7 and 8.0. After incubation for 10 
minutes at 37 °C, samples were boiled, cooled and assayed 
for of the amount of bradykinin formed. The 
results are shown in table 20 and figure 24. 
pH value 
Amount of bradykinin ng calculated to be 
formed by perfusate collected during 
the first 75 sec after shock 
Expt. I Expt. II Expt. III 
5.7 - 21.3 0 
6.0 92 100.8 0 
6.25 - 142.1 46.8 
6.5 34.2 475.3 132.7 
6.75 502 624.4 182.7 
7.0 427 363.0 155.1 
7.5 347 117.0 96.5 
8.0 i08 69.9 
Table 20: Effect of hydrogen -ion concentration on 
bradykinin- forming activity of post - 







5.5 6.0 6.5 
pH 
7.0 7.5 8.0 
Fig. 24: Effect of pH on BKF. Average values are shown 
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In these experiments, optimum formation occurred at pH 
6.75. Tests were included to ensure that the amounts of 
"tris" present in the mixture did not interfere with the 
response of rat uterus to bradykinin. 
Ethylenediamine tetra -acetic acid (EDTA): 
In these experiments, aliquots from the same active 
sample, single or pooled, were incubated with substrate in 
the presence of disodium EDTA at a final concentration 
0.03 to 0.1%4 For control, one aliquot was incubated 
without any EDTA. The amount of bradykinin produced was 
estimated, and these values, in the presence and absence of 
EDTA are shown in table 21. The sequestration of calcium 
with =TA did not seem to hinder bradykinin formation. 
















Table 21: Effect of EDTA on bradykinin formation by 
post -shock lung perfusate. 
Soya bean trypsin inhibitor: 
Similarly, aliquots of anaphylactic perfusate were 
incubated in the presence or absence of soya bean trypsin 
inhibitor (2 x 10-4 g/ml final concentration). The 
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results are given in table 22. It Ras e.scert.ine4 that the 
amount of soya bean trypsin inhibitor did not interfere with 
the bioassay. The results indicate that bradykinin 
formation under these circumstances is greatly inhibited by 
soya bean trypsin inhibitor. 
Bradykinin formed by post -shock sample 
Untreated 
SBTI- treated, 







Table 22: Effect of SBTI on bradykinin- forming 
activity of lung perfusate. Amounts 
in ng. Negative values result' from 
subtractio+z. of Eke control. 
Hexadimethrine bromide (antagonist of heparin): 
Similarly, aliquots were incubated in the presence or 
absence of hexadimethrine bromide. The results, presented 
in table 23, do not indicate any marked inhibition in the 
concentrations employed. 
Bradykinin formed by post -shook sample 
Untreated 
Hexadimethrine bromide- treated, 
final cone. g/ml 
5 x 10 





Table 23: Effect of hexadimethrine bromide on 
bradykinin- forming activity of lung 
perfusate. Amounts in ng. 
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To summarise, experiments in this section indicated 
that bradykinin- forming activity in anaphylactic lung 
perfusate was comparatively resistant to heat but could be 
destroyed by heating, had an optimum pH between 6.5 and 7.0, 
and a sharp ait -off at about 6.0. It was suppressed by 
soya bean trypsin inhibitor, but not by hexadimethrine 
bromide or by disodium ethylenediamine tetra -acetic acid, 





KININASE ACTIVITY IN GUINEA -PIG 
LUNG PERFUSATE 
KININASE ACTIVITY IN GUINEA -PIG 
LUNG PERFUSATE 
The experiments described in this section were begun 
to see if kininase (bradykinin-destroying) activity was 
present together with the forming activity in guinea -pig 
lung perfusate. When such activity was found, further 
experiments were done to investigate the effects of 
(a) incubation period, (b) heat, (o) pH, (d) disodium 
EDTA, (e) hexadimethrine bromide, and (f) soya bean 
trypsin inhibitor on this kininase activity. 
In order to estimate kininase activity, 1 ml of 
saline oontaining 100 ng synthetic bradykinin, was 
incubated with a sample of perfusate usually representing 
15 seconds perfusion. After incubation, the reaction 
mixture was boiled in a water bath for 4,5 minutes to stop 
the reaction, cooled in ice and assayed against bradykinin 
on rat uterus the same dey or stored at -10 °C. The 
difference between the original amount and the amount left 
in the reaction mixture indicated the amount destroyed. 
Preliminary experiments showed that considerable kininase 
activity was present in the perfusate. 
Period of incubation: 
Mixtures of lung perfusate and synthetic bradykinin 
were incubated and aliquots were withdrawn at various 
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intervals from 2i to 40 minutes. The amount of bradykinin 
destroyed was calculated as a percentage of the original 
amount present. The results are shown in table 24 and 
figure 25. It can be seen that progressively greater 
proportions of bradykinin were destroyed with increasing 
periods of incubation, until after 40 minutes, only about 
10¡6 was left. 
Expt. 
no. 
Bradykinin ng destroyed (out of 
100 ng) by various periods 
of incubation 
2.5 5 10 20 40 
rains. mins. mins. mins. mins. 
1 6.4 52.9 
2 41.9 61.4 65.9 
3 52.0 70 76 
4 9.5 20.0 63.3 75.5 
5 50.0 74.0 92.2 
6 44.6 83.2 93.8 
Mean 
loss 
9.5 26.1 54.0 70.5 84.0 
Table 24: The time - course of bradykinin destruction 
by kininase activity in guinea -pig lung 
perfusate. 
Heat: 
In each experiment, aliquots representing 15 second 
perfusion were taken from a single perfusate sample 
collected during 75 seconds. The untreated (control) 
sample was kept at room temperature (18 °C). Others were 
heated at 56 °C from 5 to 30 minutes, or at 100 °C from 2 to 
15 minutes. After heating the samples were cooled quickly 
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Fi,g, 25 Time- course of braáykinín- destruct n by 
kínínase. in lung periasaf -e 
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to room temperature. The control and heated samples were 
incubated with 100 ng bradykinin, and kininase activity 
expressed in terms of the amount destroyed. The results 
are shown in table 25. Kininase activity was barely 
detectable after heating at 56 °C for 30 minutes or at 100 °C 
for 10 minutes; much is destroyed by 3 minutes at 100 °C. 
Unheated 
/ Heated at 100 °C for 
mins. 
Heated at 56 °C for 
mins. 
2 3 10 5 10 30 
226.0 30 - - 
264..5 - 0 - 
322.5 - - 0 
230.5 154.5 138.0 - 
208.0 62.5 16.0 - 
180.0 126.0 92.0 16.0 
Table 25: Effect of heat on kininase activity. The 
figures represent the calculated amount of 
bradykinin ng destroyed by 1 minute 
collection of lung perfusate 
pH: 
Aliquots from the same sample of perfusate were 
incubated at pH values, from 5.7 to 8.0, maintained by 0.03 
M phosphate buffer. The kininase activity at different 
pH values, expressed in terms of bradykinin destroyed, are 
shown in table 26 and figure 26. The pH value for 
optimum kininase activity was between 7.0 and 7.5, and 
the activity was very greatly reduced by small changes of 

















6.4 4.7.8 27.0 
6.6 60.2 45.3 
6.8 3.0 36.0 67.4 65.6 
7.0 21.0 37.7 5.8 76.4 73.2 83.0 
7.1 59.2 83.8 
7.2 54.2 51.6 87.4 90.3 73.4 
7.3 52.6 88.4 
7.4 27.4 41.0 81.8 
7.6 16.8 75.4 
8.0 12.0 
Table 26: The effect of pH on kininase activity. 
The figures represent ng destroyed, 
out of 100 ng bradykinin by perfusate 
collected over 15 seconds. 
EDTA: 
Braâykinin was incubated with perfusate in the presence 
and absence of EDTA (final concentration 2 x 10' to 10 
-3 
g/ml). The mixture was incubated for 20 minutes, and 
compared with control samples. The findings are shown in 
table 27. Very little inhibition occurs. 
Hexadimethrine bromide and soya bean trypsin inhibitor 
(SBTI): 
1 ml Tyrode containing 100 ng bradykinin was added to 










6.0 6.4 .6 .8 7.0 .2 .4 .6 8.0 
pH 
Fig. 26: Effect of pH on kininase activity. The 
ordinate shows the amount destroyed out 
of 100 ng when incubated with perfusate 
collected during 15 seconds. The 
different curves represent individual 
experiments. 
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or 20 second collection. To this mixture, either 1 ml 
Tyrode (to obtain control incubate) or SBTI (to give final 
concentration of 2 to 5 x 10 
-4 
g/mi) or hexadimethrine 
bromide (final concentration 5 x 106 g /ml) was added. 
After incubation for 20 minutes, the samples were boiled 
and cooled to room temperature. The estimated kininase 
activity is shown in table 27. Neither hexadimethrine 
bromide nor SBTI seemed to inhibit kininase activity in 
the concentrations employed. 
Control 
SBTI conc. g/ml 
















EDTA conc. g/ml 




Table 27: Effect of soya bean trypsin inhibitor 
(SBTI), hexadimethrine bromide and 
EDTA on kininase activity of lung 
perfusate. The concentrations shown 
refer to the final concentration in 
the reaction mixture. Other figures 
represent ngs bradykinin calculated 
to be destroyed by perfusate collect- 
ed over one minute. 
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The amounts of kininase present in the effluent during the 
course of anaphylaxis in perfused guinea -pig lung: 
Kininase activity was estimated in perfusate samples 
collected before and at various times after challenge. The 
findings are shown in table 28, and figure 27. Anaphylaxis 
did not seem to produce any significant alteration of 
kininase activity which is apparently present in normal 
tissue and spontaneously released during perfusion. 
Time in minutes 
after shock 
Experiment no. 
1 2 3 4 5' 
Control 
0 to 1 
1 to 3 
3 to 5 
S to 7 
5 to 10 


















Table 28: Amount of bradykinin destroyed on 
incubation for 20 minutes with 
perfusate obtained in one minute, 
during the period shown. Amounts 
in ng. 
To summarise, experiments described in this section 
indicate that blood -free guinea -pig lung perfusate has 
considerable kininase activity, not appreciably altered by 
anaphylaxis. The kininase activity is thermolabile, has an 
optimum pH level between 7.0 and 7.5, and is very little 
affected by EDTA. Hexadimethrine bromide or soya bean 



















Fig. 27: Effect of anaphylactic shock on kininase activity in 
lung perfusate. Figures refer to the amount of 
bradykinin calculated to be destroyed by perfusate 






The experiments in this section were done to 
investigate whether bradykinin increases bronchial 
mucosecretion. 
As there are no standard methods for estimation of 
increased bronchial mucosecretion, the following method was 
adopted after some preliminary trials. This was based on 
the principle that in an isolated lung with the bronchial 
tree filled with physiological fluid, bronchial muco- 
secretion would be reflected in the mucoprotein content of 
the fluid in the lung. Mixing would result from rhythmic 
inflation, and the movement of fluid would permit sampling 
on the addition of drugs. 
A glass chamber was set up as shown in figure 28 and 
made airtight with bungs A and B. Circulation of water at 
37 °C through its double walls kept it warm. A glass 
oannula about 5 cm long was passed through the centre of A 
about 1 cm into the chamber. A glass tube D was passed 
through another hole in A, and was connected to a three -way 
glass tap which led to compressed air and vacuum respect- 
ively. D was also connected with a mercury manometer. 
A guinea -pig 300 -400 g was killed by breaking the 
neck and the lungs removed along with the trachea. The 
cannula was tied into the trachea, and the preparation 
was thus suspended in the closed chamber. 















Fig. 28: Assembly for estimation of bronchial mucosecretion. 
The manometer records both positive and negative 
pressure. An adjustable valve for limiting both 
positive and negative pressure can be attached to 
a side branch (not shown) of tube D. 
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the tracheal cannula. It was found necessary to 
introduce this amount somewhat slowly to achieve proper 
filling up of the lung. Using air pressure or vacuum, 
the pressure in the chamber was raised and lowered 
alternately; as a result, the lungs were inflated and 
deflated rhythmically. This was done 10-15 times a 
minute for 10 minutes to establish a steady state. At 
intervals, samples (2 ml) were withdrawn, or bradykinin 
introduced via a narrow polythene tube which was passed 
down the cannula into the trachea. The fluid withdrawn 
was replaced immediately with an equal amount of Tyrode. 
From the mucoprotein content of the fluid, estimated 
according to the method described by Winsler (1955), 
the total amount of mucoprotein in the entire fluid in 
the pulmonary tree was calculated. For this purpose, only 
the amount of fluid experimentally introduced was taken 
into account. After correction for amounts taken away 
in successive samples, the total amount of mucoprotein 
present in the system was calculated in control and post - 
bradykinin samples. The results are shown in table 28 
and figure 29. The rise in mucoprotein content in 
post- bradykinin samples as compared with successive 
control samples, is at best equivocal. 
Histological confirmation of these results was 
attempted. SJie.ds ° of normal lungs, and lungs from 
guinea -pigs; 30 minutes after i.v. administration of 
0.5 and 1.0 jg/kg bradykinin,were removed, fixed in Susa 
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8 O 2 
Minutes 
Brad yk in in 
6 1O 
Fig. 29: Amount of mucoprotein estimated to be present 
in bathing fluid in isolated lung; interrupted 
lines represent estimations before coming in 
contact with bradykinin 
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solution and stained with Mayer's haematoxylin and counter - 
stained with alcian blue (by courtesy of Mr Peter Eyre of 
the Royal Dick Veterinary College, Edinburgh). The 
counterstain which would have brought out any mucus, failed 
to show any significant difference between normal and 
bradykinin- administered samples. 
Time in minutes 




0 4 8 in system 10 14 18 
10.0 25 17.2 
7.7 10.8 11.5 2.5 17.3 13.96 
7.5 8.4 11.0 0.9 12.3 9.9 12.6 
5.1 6.0 7.5 2.5 6.8 11.4 
15.5 15.2 13.9 nil 14.7 15.7 15.7 
9.7 9.6 12.2 3.0 14.4 14.2 14.9 
0 o 0 2.5 0 0 6.4 
Table 28: Bronchial mucosecretion. Effect of 
bradykinin on the amount of muco- 
protein (mg in the whole experimental 
system). 
To summarise, mucoprotein content of Tyrode solution 
kept in contact with the respiratory tree could not be 
shown to alter significantly after administration of brady- 
kinin. 
PART III 
D I S C U S S I O N 
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DISCUSSION 
In the course of the various sections presenting the 
results, some comments have been made on the aim and 
rationale of the experiments, and occasionally on the 
significance of the results. The purpose of this chapter 
is to discuss the various facets of the investigation and 
to integrate their significance. 
The investigation was undertaken for a number of 
known tkaL 
reasons. Tt NF`asc;:lo r e finproteolytic activity in blood 
r_ associated with anaphylaxis. It is also known 
that increased amounts of urokinase occur in the urine of 
the guinea -pig after anaphylactic shock (Damgaard and Ungar, 
1952). It seemed probable that such activated protease(s) 
might split bradykininogen, which is normally present in 
blood, and thus release bradykinin. Indeed, bradykinin is 
released in blood somewhat easily - by such simple measures 
as exposure to glass or dilution in physiological solutions. 
Furthermore, the main pharmacological effects of bradykinin, 
vasodilatation and increased capillary permeability: lead- 
ing to hypotension, smooth muscle contraction, stimulation 
of sensory endings in the skin2and leucocyte migration, 
correspond to some of the features of anaphylaxis. This 
might account for certain phenomena which cannot be 
explained adequately on the basis of other active substances 
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known to be present during anaphylaxis. Finally, it was 
hoped that new data on the formation and destruction of 
bradykinin might shed light on its possible role in other 
pathological conditions. 
A note on terminology is due here, particularly the 
use of the word " bradykinin" instead of the more general 
term "plasma .::kinin ". Plasma kinin consists of bradykinin 
and /or other closely allied polypeptides with similar 
pharmacological properties. When this investigation was 
started, only bradykinin had been purified and synthesised; 
the structure of a second kinin (kallidin II) was determined 
much later. Hence, bradykinin was used as a standard in 
these investigations, and biological activity found to be 
bradykinin -like was measured against and expressed in terms 
of synthetic bradykinin. So the " bradykinin" referred to 
in the course of the present experiments should be taken to 
mean "bradykinin or polypeptides which cannot be distinguish 
ed from it pharmacologically ". It is possible that part 
of the activity in the course of these experiments was due 
to kallidin and /or other kinins, but this would not 
materially change the significance of the present results. 
Even when other kinins are available in chemically pure 
form, preferably with specific antagonists, their separate 
and simultaneous estimation in biological material will be 
difficult; at present it is not possible. 
There is only one report of the possible involvement of 
bradykinin in anaphylaxis (Beraldo, 1950)land subsequent 
work by Schachter (1956) and Armstrong et al. (1957) had 
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shown that the method used in 1950 was not satisfactory. 
Beraldo added the whole blood of anaphylactic dogs, taken 
"before and several minutes after shock ", directly to an 
isolated guinea -pig ileum preparation in the presence of 
mepyramine. Seven out of 18 post -shock samples caused a 
slow contraction of the gut. The degree of activity 
present varied considerably, and some samples had to be 
incubated before any activity was found. On account of the 
wide variability and the small amount present, Beraldo 
suggested that bradykinin was unlikely to play any 
significant part in anaphylaxis. In 1950 it was not known 
that exposure to glass or dilution in physiological solution 
activated plasma to form kinins; nor had the kininase 
activity normally present in blood been realised. It is 
possible that glass- activation and/or dilution- activation 
could account for some of Beraldo's results. Glass - 
activation is the most likely explanation of samples which 
showed no activity "immediately after they were withdrawn ", 
but where "activity could be observed after incubation of 
the blood samples ", presumably in a glass container. 
Dilution -activation must also be considered since blood 
samples were put directly in the organ bath. Finally 
the amount of bradykinin present in the post -shock samples 
must have been influenced by kininase activity during the 
interval between the withdrawal of the sample and biological 
assay. No precautions are recorded, and this time -interval 
presumably varied in different experiments. Therefore in 
1960 it seemed necessary to re- examine the whole matter 
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using methods designed to prevent changes consequent upon 
withdrawal of blood. 
Bradykinin levels in blood had to be studied to 
examine the effect of anaphylaxis on bradykinin release in 
vivo. No method was available for the estimation of 
bradykinin in circulating blood, and such a method had to be 
developed first. In shed blood, formation and destruction 
of bradykinin proceed simultaneously. A suitable estimati 
method must ensure as far as possible that interfering 
enzyme activity is suppressed, and that bradykinin is 
neither formed nor destroyed spontaneously. In the present 
method advantage was taken of the fact that bradykinin is 
soluble in ethanol -water mixture, and interfering enzyme 
activity will be checked by 70-80% ethanol and also 
iminished by cold. Therefore arterial blood was run 
straight into cold ethanol so as to have approximately 80% 
ethanol in the final mixture. Whole blood rather than 
plasma was used to avoid bradykinin loss due to kininase 
activity during the 10-15 minutes required to separate 
plasma from whole blood. The use of whole blood resulted 
in the extract containing IC+ from the erythrocytes, but this 
did not lead to any serious difficulties in assay, except 
that it imposed a minimum degree of dilution of the samples 
(usually at least fivefold) before testing on the rat uterus. 
The difficulty can be partly obviated by reconstituting the 
dried material in saline instead of de Jalon solution. 
Errors due to K+ are unlikely because of the different 
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time - course of the response of the uterus: the quick 
contraction of K} can be easily distinguished from the 
slower contractions due to bradykinin and there is little 
summation. The need for a certain amount of dilution 
lowers the limit of detection to levels of the order of 
5 ng/ml blood. The experimental limitations imposed by 
the present method concerns only control samples and others 
of very low activity; due to the high sensitivity of the 
rat uterus, active samples were nearly always diluted far 
more than fivefold. Hence for the sake of simplicity, 
further purification was not attempted. If further 
purification is desired, various possibilities exist, e.g. 
ion exchangers, butanol extraction, or extraction with 95% 
ethanol in the presence of sodium chloride. In control 
samples, the amount of bradykinin present was usually 
below the threshold detectable by assay. After 
anaphylactic shock, however, in all cases the levels rose 
well above the threshold detectable. Thus the true 
increase will sometimes be slightly larger than that 
quoted in the results. 
Acute anaphylactic shock produces a distinct but brief 
rise of bradykinin level in blood in all three species 
examined ® guinea -pig, rat and rabbit. Clinical allergic 
conditions are often chronic in nature and perhaps from this 
point of view, intraperitoneally challenged guinea -pigs offer 
a better model than intravenously challenged animals. When 
antigen is slowly released from a depot, as with alum- 
adsorbed preparation from the guinea -pig, the sudden and 
usually fatal release of large quantities of histamine does 
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not occur. Under these circumstances, bradykinin is 
released over a long period. Such a gradual application of 
antigen would occur when pollen is inhaled or allergen 
comes in contact with the skin. 
If bradykinin plays any part in anaphylaxis its 
formation and release should conform to a time - course 
consistent with the speed of events during anaphylactic 
shock in the animal studied. The present experiments 
showed that in acute shock the time taken to reach peak 
blood bradykinin level conformed roughly to the time taken 
for anaphylactic features to develop in the species 
examined. For example, in the guinea -pig, peak blood 
bradykinin level is reached in 2i minutes. The same time - 
pattern is seen when anaphylaxis is induced in vitro in 
perfused guinea -pig lung and skin; a high level of 
bradykinin forming activity appears in the first one or two 
minutes following challenge. When anaphylactic guinea -pig 
lung perfusate is incubated with the substrate it would 
normally act on in vivo, i.e. fresh guinea -pig plasma, 
the same time- pattern is seen. Under these conditions, 
maximal bradykinin formation occurs in 2- 3 minutes, 
corresponding to a total delay after challenge in vivo 
of 3-4 minutes. These findings correspond in a general 
way to the speed of events seen during anaphylaxis in vivo 
in guinea -pig. 
The fall of blood bradykinin level is presumably due to 
kininase activity. This is known to be present in blood, 
and as the present findings suggest, in tissue also. 
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The ubiquity of kininase is probably responsible for the 
comparatively quick reduction of the raised bradykinin level 
in blood, in case of intravenous challenge. It should also 
be noted that the hypotensive effect of intravenous brady- 
kinin is short -lived; recently the biological half -life of 
bradykinin has been calculated as ( 0.5 minutes in women 
(Saameli and Hakes, 1962). 
The active principle in anaphylactic blood was 
identified as bradykinin -like by parallel quantitative 
assay, the effect on rat duodenum, and ehymotrypsin 
digestion. Histamine, acetylcholine and 5- hydroxytryptamine 
could be excluded by the use of antagonists. The highest 
index of discrimination was 2.0,which is reasonable 
considering the comparatively crude nature of the extract 
but could indicate the presence of other kinins e.g. 
kallidin II. In rats made resistant to histamine and 
5- hydroxytryptamine with antagonists, anaphylaxis lowers 
blood pressure; so does bradykinin. This indirect but 
supportive evidence suggests that bradykinin plays a part 
in the features of anaphylaxis. Taken with the rise of 
blood bradykinin level in rat during anaphylaxis, bradykinin 
release might explain the findings of Sawa]. and West (1958) 
who found that rats could be severely shocked with antigen 
even when they were protected against histamine and 
5- hydroxytryptamine with antagonists. This may also 
explain the finding of Brocklehurst, Humphrey and Perry 
(see later) that cutaneous manifestations in rat due to 
antigen- antibody reaction were largely mediated by somethin_ 
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other than histamine and 5- hydroxytryptamine. 
The release of bradykinin in blood after anaphylaxis 
should lead to a depletion of its bradykininogen content: 
this was investigated. Experiments with trypsin -digested 
plasma (Schachter, 1956) gave a very poor yield, presumably 
due to kininase and perhaps anti -kininase activity of 
plasma. The other methods in which plasma is fractionated 
(Holdstock, Mathias and Schachter, 1957) to obtain 
preparations with better yields, are unsuitable for small 
samples (0.2- 0.5 ml plasma), not least because two 
dialysis procedures are involved. In the development of 
a suitable and simple method it was felt that the crucial 
procedure would be to suppress all enzymic activity as 
quickly and completely as possible. In the present method 
this was achieved by ice -cold ethanol in excess; full 
denaturation resulted from subsequent boiling. This 
method has a further advantage. Ethanol precipitates 
bradykininogen with other proteins, but as bradykinin is 
ethanol -soluble, examination of the supernatant permits a 
determination of the free bradykinin present in plasma in 
parallel with the estimation of bradykininogen from the 
precipitate. Diniz, Carvalho, Ryan and Rocha e Silva 
(1961) have described a method for estimation of 
bradykininogen in small samples. In this, denaturation is 
effected by boiling in dilute acetic acid. With this 
method, these workers found an average of 8.8 jag/mi plasma 
(range 7.9-10) in the guinea -pig ( bradykininogen expressed 
in terms of the amount of bradykinin formed on trypsin- 
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digestion). This is lower than the average value obtained 
by the present method (12.86)ug/ml, S.E. 1.9). in order to 
compare the efficiency of the two methods, bradykininogen 
content of aliquots from the same samples of guinea -pig 
plasma were compared in parallel employing the two methods. 
As table 30 shows, better yields were obtained with the 
method klem- 2.4 in the course of this work. 
Bradykininogen E bradykinin ,ig/ml plasma; 
estimated according to the 







Table 30: Comparison of bradykininogen yield 
from plasma by the present method 
and that of Diniz et al. (1961) 
* The average bradykininogen 
value reported by these 
workers is = bradykinin 
8.8 pg/ml plasma 
The very recent paper -of Henriques, Picarelli and Oliveira 
(1962), shows that the enzymes in the plasma of certain specie, 
(horse) are in fact activated by incubation at pH 4, so that 
some loss of bradykininogen might occur during heating to 
100 °C. For comparison of control and post -shock samples, 
guinea -pigs were challenged intraperitoneally because with 
retarded and comparatively long -lasting shock, bradykininoge 
depletion was more likely to be detected. It soon became 
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evident that the amount of bradykininogen used up was far in 
excess of the amounts one would expect from the peak blood 
bradykinin levels. For example the depletion of brady- 
kininogen is of the order of = 6 jig bradykinin per ml 
plasma; this is about 50 times the peak bradykinin level 
found in blood (i.e. 50 ng/ml = approximately 100 ng/ml 
plasma) during anaphylaxis. The difference is easily 
understood when one considers the high level of kininase 
activity normally present in tissue apart from that in the 
blood. The levels of bradykinin detected during 
anaphylaxis reflect: a dynamic process; bradykininogen is 
split to release bradykinin, and simultaneously the 
bradykinin is being destroyed by kininase present in tissue 
and blood. When formation exceeds destruction, the level 
of free bradykinin in blood rises. Since it must be 
presumed that the rate of destruction will rise with 
increase in the concentration of bradykinin, the system 
tends to be self -limiting and high concentrations of 
bradykinin may never occur. The present results show that 
in retarded -type anaphylaxis large amounts of bradykininogen 
are lost. Therefore the gross amount of bradykinin formed 
is probably considerable; however, the net amount of 
bradykinin present in blood at any one time is small because 
of continuous destruction. Nevertheless, the low 
concentration is likely to be above threshold for many 
tissue responses, particularly that of raised vascular 
permeability, so the presence of bradykinin for long periods 
may account for some of the manifestations of allergy and 
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asthma. 
The release of bradykinin, with concomitant depletion 
of bradykininogen led to an investigation of the site and 
mechanism of bradykinin formation following anaphylaxis. 
Two situations in which bradykinin may be formed were 
investigated: (a) challenge in vitro of shed blood, in the 
absence of tissue; and (b) challenge in vitro of tissue in 
the absence of blood. The role of histamine was also 
considered. In the first case, significant release of 
bradykinin could not be detected in the blood of either 
guinea -pig or rat. This would suggest that some factor 
from tissue is essential for anaphylactic bradykinin release 
in blood. 
Since no bradykinin was released on challenge of shed 
blood, blood -free tissue was next examined. Skin and lung 
were chosen for this purpose for practical reasons and also 
because these tissues are of particular interest in allergic 
etate. 
During investigation of possible bradykinin formation 
in skin during anaphylaxis in vitro it is essential to avoid 
activation of proteases during experimental manipulations. 
The usual skin perfusion procedure (Feldberg and Paton, 1951) 
is not suitable since the use of a thermocautery is very 
likely to activate proteolytie enzymes; indeed, bradykinin 
is said to be released by damage of the skin by heat (Rocha 
e Silva and Antonio, 1960; Rocha e Silva and Rosenthal, 
1961). The present preparation avoids these difficulties 
as far as possible. However, it has certain limitations. 
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While ink -injected specimens (figure 17) suggest good 
perfusion, the actual proportion of the total vascular bed 
which is actually being perfused will vary from preparation 
to preparation and perhaps in the same preparation from time 
to time. This factor, which will largely determine the 
extent of antigen -antibody reaction achieved, may explain 
the considerable variation in the level of the peak 
bradykinin- forming activity reached after anaphylaxis. 
The general pattern of response, however, remains the same 
in every experiment, i.e. a sharp rise in the first minute 
followed by decline over the next few minutes. In some 
experiments attempts were made to keep a high proportion of 
the vascular bed open by perfusing under greater pressure, 
but oedema appeared soon, and the preparations had to be 
abandoned. With the usual pressure head (150 cm water) 
oedema appears only after 4.5 to 60 minutes of perfusion. 
The absence of bradykinin in the perfusate is not 
surprising, since bradykininogen is presumably absent in 
these blood -free preparations. These experiments indicate 
that anaphylaxis results in the rapid release of a 
substance(s) capable of forming bradykinin on incubation 
with bradykininogen. For easy reference, this will be 
referred to as BKF (Bradykinin Forming Factor). The 
extremely rapid rise in BKF level after anaphylaxis points 
to an almost explosive release, which is faster than that 
of SRS -A (Brocklehurst, 1960) and is of the same order as 
histamine. Hence the possibility was considered that BKF 
release was not initiated by the antigen- antibody reaction 
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itself, but by the attendant histamine release which might 
induce leakage of BKF from the tissue and thence into the 
blood vessels due to increased permeability. Since 
histamine administration did not increase BKF, its release 
cannot be dependent upon histamine, though the increased 
permeability due to histamine is probably an accessory 
factor. These findings differ from those of Edery and 
Lewis (1962b) who found that the increased bradykinin- 
forming capacity of lymph from a dog's hindlimb subjected 
to burning, trauma or reactive hyperaemia could be 
reproduced by histamine. These workers did not find any 
increase in BKF in the effluent from a perfused limb after 
injury. The experiments are different in many respects 
(e.g. species, organ and nature of injury) - quite apart 
from the presence of blood and route of collecting the 
active material. It may be that in the intact limb 
something akin to dilution - activation occurs when the 
vascular permeability alters, and histamine would then 
produce such an effect. In the anaphylactic reaction, the 
damage would extend progressively from the vascular supply 
to the other tissue, and very slowly to the outer epidermis, 
whereas in the experiments of Edery and Lewis (1962) the 
damage would originate extravascularly, and the sequence and 
probably the mechanism may be quite different. Edery and 
Lewis incubated the enzyme- containing material with substrate 
for two minutes, and do not mention whether longer 
incubation periods were also tried. The time of incubation 
may be important because in the present work it was found 
that whereas the optimum time for incubation using fresh 
homologous plasma as substrate was about 2 minutes, the 
optimum time when heated dog plasma pseudoglobulin was used 
was about 1O minutes, and very little bradykinin is present 
after 2 minutes. These two substrates are comparable with 
those used by Edery and Lewis in the lymph collection and 
perfusate collection respectively. 
Skin is known to contain proteases (Beloff and Peters, 
1945; Neville -Jones and Peters, 1948). It has been 
reported that acetone -dried rat skin does not yield 
protease except with drastic procedures like extraction 
with potassium thiocyanate, and such thiocyanate extracts 
have been shown to form plasma kinin on incubation with 
suitable substrate (Lewis, 1959). An easier extraction 
procedure, with buffered KC1, was reported by Inderbitzin 
and Goetschmann (i959). They separated two enzymes from 
acetone-dried rat skin. One was comparatively thermostable 
and acted optimally in neutral or slightly alkaline solutions. 
The amount of this enzyme present in skin does not alter 
after occurrence of PCA (Passive cutaneous anaphylaxis) in 
skin. The other enzyme was more thermolabile and acted 
optimally at an acid pH. Skin previously subjected to 
PCA contains less of this enzyme than normal skin. These 
workers therefore suggested that increased capillary 
permeability produced in the rat by PCA is due to the 
release of a proteolytic enzyme. It is possible that this 
was a bradykinin- forming enzyme because the present work has 
shown loss of BKF into the perfusion fluid during 
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anaphylaxis and this is active in neutral or slightly active 
media. Inderbitzin and Goetschmann (1959) found that the 
increase in cutaneous capillary permeability in anaphylaxis 
is reduced by antiproteolytic agents. The nature of the 
protease was not established, but this work suggests that 
bradykinin -like active substances may be important. 
The lung, as the shock organ in the guinea -pig was 
chosen for most of the experiments in vitro. The absence of 
bradykinin itself in the shocked lung perfusate confirmed the 
earlier observation of Brocklehurst (1958x), though it is 
only to be expected in a blood -free system. There was an 
explosive release of BKF after shock, the time - course being 
very similar to that of histamine. This distinguishes it 
from the time- course of SRS -A release as elicited by 
Brocklehurst (1960). The possibility that BKF release was 
due to the increase in permeability and contraction produced 
by histamine was considered, and excluded by the control 
experiments where histamine, but not antigen, was 
administered. In lung, as in skin, the permeability - 
increasing and contractile effect of histamine does not 
initiate BKF release, but probably promotes its effect by 
facilitating its contact with bradykinïnogen from blood.. 
The time - course, of BKF release and the speed of action 
on plasma or lymph could produce bradykinin quickly enough 
to play a part in the guinea -pig even when collapse occurs 
within 3 or 4. minutes. 
In the present investigation no attempts were made to 
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elucidate the mechanism of BKF release from lung. However, 
there is a rough correspondence in the amount of BKF and 
histamine released, as also the time- course of release. One 
may speculate that the steps leading from antigen- antibody 
reaction to histamine release and BKF release have a large 
part in common, simply involving sufficient cell damage to 
cause loss of histamine from mast cell granules or protease 
from lysosomes. 
After the release of bradykinin in vivo was detected it 
was felt desirable to study this in different tissues and 
species. Rapp (1962) found that in the rat, antigen - 
antibody reaction in the peritoneal fluid results 
in the appearance of SRS -A. In these experiments, 
antibody is given intraperitoneally 4. hours before antigen. 
This procedure was followed, but even control samples had 
considerable bradykinin -like activity. The activity in 
post -shock samples was not sufficiently enhanced to permit 
any conclusions. then Tyrode was used instead of saline, 
control values were lower. This indicates that bradykinin 
is formed in rat under conditions which deviate only slightly 
from normal p hysiolCgy; indeed, large amounts of bradykinin 
are formed in rat plasma comparatively easily (Rocha e 
Silva and Holzhacker, 1959). In the present experiments 
the usual precautions against spontaneous activity 
(siliconed glassware, storage on ice) were taken, but the 
interval between collection of the samples and their assay 
varied from a few minutes to about two hours; in every 
ease control levels of bradykinin were too high to permit 
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satisfactory experiments. It might be instructive to 
apply the technique used by Rapp (1962) to the guinea -pig 
because the mast cells of this animal are known to be 
less easily destroyed. 
It was necessary to obtain some information concerning 
the properties of BKF. The formation of bradykinin on 
incubation of BKF with pseudoglobulin substrate has been 
assumed to be enzymic, though it is still a little uncertain 
whether BKF is the enzyme itself or an activator of the 
precursor of a bradykinin- forming enzyme known to be present 
in the dog globulin substrate employed. This question can 
be settled only when pure bradykininogen is available, or at 
least partially purified bradykininogen, free from forming 
or destroying enzymes or their precursors. Soya bean 
trypsin inhibitor inhibits BKF activity, but as it inhibits 
kallikrein this does not necessarily prove that BKF itself 
is an enzyme. BKF is more heat -resistant than kininase, 
though the difference is not so marked as to permit the 
selective destruction of kininase while BKF is left intact. 
The question that BKF might be the same as the enzyme which 
forms bradykinin on glass -activation or dilution 
was considered (Armstrong et al., 1962). This question wil 
have to be left open as the available evidence does not 
permit a firm conclusion. Hexadimethrine bromide inhibits 
the enzyme purified by Armstrong and her colleagues at a 
final concentration of 2 to 5 x 10 
-6 
g /ml, To compare 
BKF with this enzyme, the effect of hexadimethrine bromide 




g/ml produced practically no reduction in BKF activity. 
This argues against BKF which comes from tissue being the 
same as the enzyme activated in plasma. However, it should 
be remembered that different substrates were used in these 
experiments (dog pseudoglobulin and human plasma) and the 
results therefore are not strictly comparable. 
From the experiments described in section VII the best 
pH for bradykinin formation by BKF would appear to be 
approximately 6.75; this was not known at the time of the 
earlier experiments where the release of BKF was establishe 
In these experiments pseudoglobulin was incubated with 
Tyrode perfusate, hence optimal conditions were not 
employed. Even under these circumstances, the pattern of 
response is quite clear. 
The present findings on the effect of pH on BKF 
activity is interesting. A slightly acid milieu (pH value 
6.5 to 7.0) is best for the release of bradykinin. It is 
probable that in bronchial asthma hypercapnia and the 
usually attendant emphysema may lead to respiratory 
acidosis and favour bradykinin formation. In other 
pathological conditions such as burn, trauma and reactive 
hyperaemia where bradykinin is suspected to play a role, 
the release of acid metabolites like lactic acid, CO2 and 
phosphoric acid may lead to a local lowering of pH to 6.5 to 
7.0 and thus favour bradykinin formation. At this pH 
1d.ninase activity is considerably reduced. The net amount 
of bradykinin present is a balance between the simultaneous 
processes of formation and destruction. A slightly acid 
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pH, quite capable of being reached in tissue subjected to 
mild oxygen lack would therefore tend to raise the net 
level of bradykinin present by both increasing bradykinin 
formation and reducing destruction. It is of interest to 
recall that pus and some exudates are acidic in nature. 
Because nothing is known yet of the substrate speci- 
ficity of BKF, no opinion can be formed about possible 
relationship between BKF and the chymotiypsin like enzyme 
which Austen and Brocklehurst (1961a) consider to be 
essential for anaphylactic release of histamine from 
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guinea-pig lung; a priori there would seem to be no 
relationship because BKF would be expected to resemble tryp- 
sin rather than chymotrypsin. 
The known occurrence of kininase activity in blood 
(Armstrong et al., 1955; Schachter, 1960) and the large 
turnover of bradykininogen in anaphylaxis, prompted tests 
for kininase activity in tissues about which little is 
known. Werle (1955) and Roches e Silva (1955) have 
referred to kininase activity in liver and kidney, but 
presumably these tissues were not perfused free of blood, 
and it is difficult to know how much of the kininase activ- 
ity detected was due to the blood present in the organs 
examined. As far as can be ascertained, the present 
experiments are the first to show the presence of kininase 
activity in tissue as distinct from blood. When kininase 
activity was found in normal guinea -pig lung perfusate, two 
aspects were considered - (a) investigation of some of the 
characteristics of the active substance which may 
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contribute to its future identification; and (b) whether 
anaphylactic shock altered the kininase activity. Brady - 
kininogen depletion in anaphylaxis suggests that raised 
bradykinin levels in anaphylaxis are chiefly due to 
increased formation. The increased bradykinin- forming 
capacity of post -shock lung perfusate could, however, be 
due in part to reduced kinin destruction. It was found 
that anaphylaxis did not alter kininase activity materially 
and apparently steady and spontaneous leakage of kininase 
occurs from lung; so reduction of kininase activity seems 
unlikely to contribute to the increased bradykinin- forming 
capacity of post -shock guinea -pig lung perfusate. 
The time -course of destruction of bradykinin when 
incubated with perfusate suggests a first order reaction 
typical of an enzyme. The kininase activity is destroyed 
by heat and is more thermolabile than BKF. Hexadimethrine 
bromide does not inhibit kininase activity. Since the 
presence of disodium ethylenediamine tetra -acetic acid 
(EDTA) during perfusate + bradykinin incubation does not 
inhibit bradykinin destruction seriously, Ca ++ probably is 
not essential for kininase activity. In this regard, the 
lung kininase activity as studied in the present experiments 
appears to be different from the plasma kininase activity 
studied by Armstrong et al. (1955), who found that the decay 
of bradykinin activity in glass- exposed human plasma was 
greatly reduced by the presence of disodium EDTA. It has 
been shown recently that leucocytes contain two types of 
kininases, one of which is inhibited by EDTA, whereas the 
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other is not (Erdös et al., 1962; Schwab, 1962). It would 
seem likely that there are several types of kininase. 
Soya bean trypsin inhibitor does not inhibit kininase 
while it suppresses BKF markedly. It may be possible to 
utilise this fact in the estimation of kininase activity in 
a biological fluid which contains kininase and BKF as well 
as bradykininogen. 
In the course of the present experiments, the optimum 
pH value for kininase activity was found to be between 7.0 
and 7.4.. There is a sharp drop in kininase activity in the 
acid side, i.e. below the 6.6- 6.8 level. As already 
mentioned, the pH- optimum of BKF between 6.5 and 6.8 may be 
significant in other pathological conditions in which it is 
suspected to play a role - e.g. reactive hyperaemia, burn 
and shock. Thus at pH 6.75 there will be optimum BKF 
activity and reduced kininase activity so there will 
presumably be a net gain of bradykinin content attributable 
solely to pH. This finding thus supports the idea that 
bradykinin is a physiological regulator in reactive hyper- 
aemia, and that it plays an active role in any tissue 
subjected to oxygen lack or an excess of acid products, 
including metabolites of the Krebs cycle, the Cori cycle and 
products of cell destruction. The bradykinin system is 
thus seen to be well fitted as a local regulator of blood 
and lymph flow in damaged or comparatively anoxic tissue, 
where it can function as a self- limiting homeostatic process 
Apart from smooth muscle contraction, another possible 
contribution of bradykinin to bronchial pathology was 
considered. Increased secretion from the mucous glands of 
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the bronchial tree plays an important part in the patholog- 
ical Changes in bronchial asthma. Such increase is not 
satisfactorily explained by histamine or 5- ydroxytryptamine, 
and the participation of bradykinin was considered. Since 
there is no experimental method for estimating rather rapid 
or short -lived changes in experimental bronchial muco- 
secretion, a method was devised. This was based on the 
premise that when the bronchial tree is in contact with a 
physiological solution, ar}r increase in mucosecretion due 
to the presence of a drug in the solution would be reflected 
in an increased mucoprotein content in the solution. To 
ensure proper dispersion of the mucoprotein in the solution, 
the lung is inflated and deflated rhythmically. However, 
the powerful bronchoconstriction produced by bradykinin 
hindered the inflation and deflation and withdrawal of 
samples. Some of the mucoprotein was probably trapped in 
those bronchioles cut off from the sampling fluid. Doses 
of 2.5- 3 ng/ml were employed and this was an unexpected 
demonstration of the bronchoconstrictor effect of brady- 
kinin in vitro. After the administration of bradykinin 
there was a slight rise in the mucoprotein content, but not 
more than in the serially collected control samples. 
Histological examination likewise did not show any evidence 
of increased mucosecretion after bradykinin administration 
i vivo. These experiments were abandoned because trials 
to improve the method seemed likely to require more time 
than could be spared. The results are inconclusive, but the 
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Fig. 30: Postulated scheme of anaphylactic release 
of bradykinin; BK = bradykinin; BKF = 
bradykinin- forming activity; BK'ogen = 
bradykininogen ;lm....3 = conversion; - - - = transport;--.--.-9.= biological 
effect; /^\,../7y = destruction. 
From the present experiments one may follow some of the 
steps which lead to bradykinin formation in anaphylaxis. 
This is shown schematically in figure 30. One would visual- 
ise that antigen -antibody reaction releases BKF from tissue; 
at the same time, released histamine increases vascular 
permeability, and brings BKF in contact with bradykininogen 
in the interstitial spaces, and perhaps within the smaller 
blood vessels also. Bradykinin formation would follow and 
further facilitate interaction between BKF and bradykinin- 
ogen by maintaining increased vascular permeability. The 
formed bradykinin probably travels freely through capillary 
walls so that it can act on the plain muscle of both blood 
vessels and organs. Formation of bradykinin progresses 
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pari passu with bradykinin destruction by kininase. The 
balance of the two processes would determine the net amount 
of bradykinin present. Immediately following the explosive 
liberation of BKF in the first minutes after challenge, 
formation exceeds destruction, and bradykinin level in the 
body rises; later, when BKF activity decreases, the formed 
bradykinin is rather quickly inactivated by the kininase 
present in blood and tissue. When BKF release proceeds for 
a considerable period, as presumably occurs in shock due to 
retarded challenge, there is a considerable turnover of brady- 
kinin, which is reflected in prolonged bradykinin activity. 
The depletion of bradykininogen is so great that eventually 
bradykinin formation must be slowed if the release of BKF 
persists. 
At present, comments on the possible role of bradykinin 
in clinical allergic states must necessarily be speculative, 
since there is a marked species variation in anaphylaxis. 
In bronchial asthma, the comparative therapeutic 
failure of antihistamine drugs suggests the participation, 
besides histamine, of other mediators. The 
non -histaminic component of bronchoconstriction in asthma 
is probably mostly due to SRS -A (Brocklehurst, 1960), but 
bradykinin may also contribute to the overall picture since 
it can cause wheezing and dyspnoea in man (Herxheimer and 
Streseman, 1961). It is not clear whether bradykinin 
contributes to increased secretion of bronchial mucous 
glands in asthma. Bradykinin may also contribute to 
prolonged allergic conditions in man by virtue of its effect 
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on the tonus and permeability of blood vessels. It is thus 
likely to be very largely concerned in oedematous conditions 
which persist much longer than would be expected if 
histamine were the responsible agent, and where anti- 
histaminic drugs are not very active. These conditions 
include oedema of the bronchial mucosa in asthma, often 
that of the nasal mucosa in hay fever, as well as chronic 
urticarial conditions. 
Bradykinin is known to produce pain and irritation 
when applied to the exposed cutaneous sensory nerve endings 
of a blister base (Armstrong et al., 1957); it is 
therefore possible that it makes some contribution not only 
to the pain and irritation of burns, but also to cutaneous 
allergic states. Furthermore, sensory endings in the 
lung and other organs may also be stimulated by bradykinin 
and lead to reflex rearrangement of the autonomic control 
of the organ involved. 
It is clear from the evidence obtained in the course 
of the present investigation that bradykinin is released 
during anaphylaxis. Does it have a major role to play, 
or is it in the nature of a pathological artefact or 
byproduct? The situation varies from species to species, 
and in any case an evaluation of the contribution of 
bradykinin to the overall picture must await the discovery 
of a suitable antagonist. In the guinea-pig, the 
quantities released must be expected to influence the 
cutaneous and vascular features of anaphylaxis, and may 
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participate in the bronchial effect also. It may well 
play a more important role in the rat, which cannot be 
significantly protected from anaphylactic shock by 
antagonists i0 5- hydroxytryptamine and histamine. 
The involvement of bradykinin in anaphylaxis may 
help to explain some of the "anomalous" phenomena in 
anaphylaxis which cannot be explained by histamine. SRS -A 
explains some of these effects but bradykinin may well be 
suited as the responsible agent in several others, 
particularly those concerning blood vessels. 
In guinea -pigs antihistaminic agents offer considerabl 
protection against anaphylaxis, but even in mepyramine- 
protected animals some distress occurs which may lead to 
collapse in strongly sensitised animals. Kallos and Pagel 
(1937) found that eosinophil leucocytesaccumulate in large 
numbers in tissue in which an immediate -type allergic 
reaction has taken place, though this follows the main 
reaction. Injection of histamine or heparin can only 
mimic this feature weakly or not at all. Transplantation 
of lungs taken from animals dying of anaphylaxis to normal 
guinea -pigs caused a great increase in eosinophil 
leucocytes a few hours later. This would suggest the 
participation of a substance formed in the tissue (Samter, 
Kofoed and Pieper, 1953). This substance is likely to be 
bradykinin, since it is known to produce migration of 
leucocyte s` Inderbitzin (1957) found that in mepyramine- 
protected guinea -pigs increase in capillary permeability 
* This does not -necessarily imply that bradykinin is selectively 
cherviat-acile. for eosinoph'cls- 
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was not reduced during PGA, suggesting that some substance 
other than histamine took a major part in the reaction. 
Further, proteolytïc agents were found to produce an 
increase in permeability, indicating that products of 
protease activity such as bradykinin are likely to be 
involved. Isolated guinea -pig uterus from a sensitised 
animal contracts when antigen is brought in contact, even 
though the preparation is refractory to histamine following 
prolonged contact with histamine (Schild, 1936). As SRS -A 
does not contract this preparation, bradykinin may be the 
active agent, provided that bradykininogen was available 
from tissue. This could be investigated by treating the 
tissue with trypsin or Bothrops venom to remove bradykinin- 
ogen before challenging the tissue. 
Some anaphylactic phenomena in rat cannot be explained 
with histamine. Sanyal and West (1958) found that pre- 
treatment with mepyramine or BOL or both did not 
significantly reduce the severity of anaphylactic shock. 
They concluded that neither histamine nor 5- hydroxytryptamin 
plays a role in anaphylaxis in rat. Similar observations 
were made with isolated sensitised rat uterus. This 
preparation is not contracted by histamine or SRS -A. 
Kellaway (1930) showed that contact with antigen contracts 
sensitised rat uterus, which means that a substance other 
than histamine is involved. Brocklehurst (1958) found 
that this phenomenon occurred even when 5- hydroxytryptamine 
activity had been suppressed with LSD, which indicates that 
the activity is not due to 5- hydroxytryptamine. Bradykinin 
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may be the substance concerned, if bradykininogen is avail- 
able from tissue. Furthermore, Brocklehurst, Humphrey and 
Perry (1955, 1960) found that when the participation of 
histamine and 5- hydroxytryptamine were excluded by 
depletion and the presence of antagonists, increased 
cutaneous vascular permeability in PCA was not abolished. 
Inderbitzin, Dobric and Goetschmann (1959) also found that 
the degree of increase in capillary permeability is not 
correlated with the amount of histamine released. The most 
likely explanation of these cutaneous reactions is the 
participation of a substance having the properties of 
bradykinin. 
The present work suggests several lines for further 
investigation. 
(1) A suitable bradykininogen- depleting procedure 
should be developed, and the effect of this in vivo, and 
on isolated tissue observed. 
(2) Further work on the nature and mode of action of 
BKF is indicated; it might be useful to examine the effect 
of analgesic- antipyretics (particularly phenylbutazone and 
acetylsalicylic acid), corticosteroids, enzyme inhibitors 
and various competitive substrates. 
(3) Additional study of the release of BKF itself, 
specially with regard to the effect of heat, pH, calcium- 
dependence, and enzyme inhibitors as also examination of 
the influence of succinic acid and maleic acid, which 
enhance anaphylactic release of histamine, and the effect 
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of general metabolic stimulants like thyroxine. 
General experiments extending the work to other species 
and tissue is desirable, particularly 'shock" organs and 
human tissue if it can be obtained without damage or enzyme 
activation. The role of bradykinin in clinical allergic 
states, particularly asthma should be investigated in view 
of its possible clinical significance. As a beginning, 
estimation of blood bradykinin level during status 
asthmaticus and perfusion of sensitised human lung, if 
obtainable, is suggested. 
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